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Abstract

ACQUIRED EPIGENETIC AND CHROMOSOMAL CHANGES IN WOMEN
TREATED FOR BREAST CANCER

By Noran Anwar Aboalela, Ph.D

A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2014

Major Director: Colleen Jackson-Cook, Ph.D.
Department of Pathology and Human and Molecular Genetics

Improved survival for women receiving chemotherapy for breast cancer (BC) has
been accompanied by the development/persistence of psychoneurological symptoms
(PNS) that compromise their quality of life. The biological basis for these PNS is
unknown, but could reflect the acquisition of soma-wide chromosomal/epigenetic
alterations. An important first step in testing this hypothesis is to determine if somatic
genetic/epigenetic changes arise and persist following treatment. To answer this
question we longitudinally studied 71 women (ages 23-71) with early-stage BC and

collected measures before chemotherapy (baseline), and 4 weeks (mid-chemo); six
months (during radiation therapy for a subset of women); and one year following the
initiation of chemotherapy. Acquired lymphocyte chromosomal instability (scored by
micronuclei frequencies [MNF]) showed a significant increase in post-treatment
compared to baseline time-points (p<0.0001), with these increases persisting for at least
one year following chemotherapy. Significant predictive associations were observed
between MNF and tumor characteristics [luminal B (lower MNF; p=0.0182); triple
negative (higher MNF; p=0.0446)], radiotherapy (higher MNF; p=0.0004), the type
of chemotherapy received (p=0.0463),

race (Caucasians > African Americans;

p=0.0037), perceived stress levels (positive-association; p=0.0123), and cognitive
flexibility domain measures (positive-association; p=0.0238). Genome-wide acquired
methylation changes were also measured in peripheral blood cells, with 1265 sites
showing significant differential methylation following chemotherapy. These sites were
localized to open sea, shores, shelves, and CpG island sequences and included sites
within genes involved in cell cycle, DNA repair, transcription regulation, signal
transduction pathways, neuronal regeneration, and immunity. To determine if the
genetic/epigenetic alterations acquired in peripheral blood cells correlated with those
in tumor cells, BC tumors from 10 participants were analyzed using a genome-wide
copy number/targeted mutations (CN/M) microarray. While no clear blood-tumor cell
correlations were detected, genome-wide CN/M evaluations showed promise for
stratifying tumors. Lastly, in an unrelated project studying a rare case of fetuses in fetu,
methylation changes acquired in embryogenesis were shown to be influenced by both
environmental and genetic cues.

In summary, acquired chromosomal/epigenetic

alterations do arise following chemotherapy (and in embryogenesis). Further
delineation of these acquired changes could increase our understanding of the
biological basis for cancer-related side-effects and help to identify “at risk” individuals.

Chapter 1
Background and Significance
Breast cancer (BC) is the most common invasive cancer in females, accounting for
about 29% of all women’s cancers (Siegel et al 2014). Although BC is the 2nd most
common cancer leading to death, advances in early detection and management have led to
an increased survival rate (Jemal et al 2010). About 89% of diagnosed women are expected
to survive at least 5 years after diagnosis (American cancer society 2013). However, the
quality of survivors’ life is inevitably affected by short and long-term side effects of BC
and its treatment (Mehnert et al 2007, Mehnert et al 2009, Winnie et al 2009, Byar et al
2006). Anxiety (Badger et al 2007), depression (Badger et al 2007), cognitive dysfunction
(Hurria et al 2007), sleep disturbances (Bender et al 2005), fatigue (Winnie et al 2009, Byar
et al 2006), and pain (Winnie et al 2009) are the most common side effects observed in
women who survive following BC treatments (Winnie et al 2009, National Institute of
Health 2004, Kim et al 2008).
The clustering tendency of these psychoneurological symptoms (PNS) led researchers
to question whether or not at least some of these symptoms might share a common
biological etiology, and whether they could be collectively treated (Kim et al 2009,
Misakowski 2006, Misakowski & Aouizerat 2007, Cleeland et al 2003). One of the most
accepted theories for a shared biological mechanism is the cytokine-induced sickness
behavior mechanism (Misakowski & Aouizerat 2007, Cleeland et al 2003, Dantzer 2001).
Despite the animal studies and the clinical evidence that support this hypothesis (Konsman
et 2002, Lee et al 2004, Cleeland et al 2003, Nozaki et al 1997, Capuron et al 2002, Raison
1

et al 2005), this mechanism has not been studied extensively in women treated for BC, nor
has it been investigated with consideration of all the PN symptoms mentioned above. While
some investigators have suggested mechanisms for a subset of these symptoms
independently (Collado et al 2006, Ahles et al 2007), no effective prevention or treatment
for the multiple symptoms associated with BC has yet been developed. Moreover, it
remains unclear how long-term side effects persist even after the recovery from BC and its
treatment, and from the inflammatory induction associated with BC and chemotherapy.
These PN symptoms are observed in a major subgroup of BC survivors (Ahles et al 2007,
Gatson-Johansson et al 1999, Janz et al 2007, Zabora et al 2001), but the reasons behind
their occurrence in only a subgroup of survivors remains unknown.
Many factors could lead to the development of these PN symptoms in a major subset of
BC survivors. Akin to the causes underlying most complex disorders, such as cancer and
psychiatric problems, the factors influencing the development of PN symptoms, such as
cognitive dysfunction and depression, are thought to include both environmental and
genetic factors (Wichers et al 2009). Examples of environmental factors include the stress
associated with the diagnosis and its treatment, nutrition, and BC therapeutic drugs. An
individual’s genetic background could affect their susceptibility to develop the PN
symptoms. Moreover, these factors could interact with each other, and could also trigger
cellular biological changes such as inflammation, which have been evidenced to associate
with sickness behavior. These observations raise many questions. In particular, how do all
these factors interact and trigger biological changes, such as inflammation, that could lead
to the development of PN symptoms in a subset of BC survivors?
A. Feinberg, who is one of the pioneers and leaders in the field of epigenetics, proposed
2

that epigenetics is an epicenter of modern medicine, serving to explain the relationships
between environment, genetic background and disease (Feinberg 2007, 2008). Epigenetics
is referred to as mitotically heritable modifications in gene expression and phenotype that
do not result from changes in genetic sequences. It plays an important role in the
development and differentiation of cells. Mounting evidence shows an additional major
role of epigenetics in inflammation and in developing cancers and psychiatric diseases
(Wierda et al 2010, Kristensen et al 2009, Pidsley 2011, Mehler 2009). Although epigenetic
changes are known by their stable heritability, they have also been characterized by their
plasticity and reversibility (Reik 2007, Narayan& Dragunow 2010). The heritability
phenomenon could explain how long-term PN symptoms persist even after the recovery
from BC and chemotherapy. The plasticity and sensitivity of epigenetics to genetic
background, environment influences, and their interactions could explain why PN
symptoms happen only in a subset of survivors. The reversibility of epigenetic changes
makes them an attractive target for manipulation and drug therapies (Narayan & Dragunow
2010).
Cytokine-induced sickness behavior: “A biological mechanism at the cellular level”
One of the cellular biological mechanisms that is thought to have an important
biological basis for the development of at least some of the PNS associated with cancer
treatment is the cytokine-sickness behavior mechanism. It is thought that inflammation
resulting from BC, or its treatment, has a role in symptom production (Cleeland et al 2003).
From animal models, preclinical, and clinical evidence it is believed that sickness behavior
requires an immune-to-brain communication. A cascade of pro-inflammatory cytokines is
initially released by the action of macrophages. This released cascade then activates other
3

immune cells, such as lymphocytes and neutrophils. Peripheral cytokines could induce
PNS through multiple pathways where cytokines are required to communicate with the
brain. Cytokines could be produced not only by macrophages, but also by other cell types,
such as tumor cells in cancer patients and nervous system cells (Reviewed in Cleeland et
al, 2003). However, this mechanism alone cannot explain the occurrence of all these
symptoms and their persistence, even after the recovery from BC and its treatments and in
the absence of inflammatory induction. Therefore, inflammation could have a basic role in
initiating the development of at least a portion of these symptoms. However, there must be
more than one mechanism, perhaps - a series of interactive events - that occurs before and
after inflammation to lead to the final observed outcome. Therefore, our hypothesis is that
while inflammation may be one of the early biological changes leading to the development
of these PNS, it is just one of a cascade of events that interact and together lead to the
development of these short and long term symptoms (Figure 1).

4

Figure 1. Schematic illustrating the hypothesized mechanism(s) leading to PN
symptoms associated with BC. Both environmental factors and genetic susceptibility lead
to the development of BC in women before receiving BC treatments. BC and its treatment,
in addition to the stress associated with the diagnosis, induce acquired biological changes
such as inflammation activation and genetic changes involved in the inflammation process.
Our hypothesis is that inflammation is one of the initiators of a cascade of events that arise,
interact, and together lead to the development of PN symptoms. These events include
acquired changes in epigenetic profiles, gene expression and chromosomal instability.
Epigenetic changes are heritable on a cellular level, but are characterized by their plasticity
and potential for reversibility. Thus, these changes are persistent, yet sensitive to genetic
environmental interactions (E X G), making them a viable therapeutic target.

5

Environmental factors and genetic susceptibility:
Environmental factors include, but are not limited to, nutritional factors, the stress
associated with BC diagnosis and its treatment, and BC treatments such as
chemotherapeutic drugs, radiation and hormonal therapies. One important nutritional
factor could be folic acid. Results of many studies have shown the important role of folate
in the DNA methylation process. Folate provides the one-carbon units required in
converting homocysteine to methionine, which is then converted to the universal methyl
donor S-adenosylmethionine (Jacob R, 2000). Folate deficiency has been associated with
birth defects and tumorogenesis (Jacob R. 2000, Blount BC et al. 1997). Moreover, folic
acid concentration correlates significantly and inversely with frequencies of micronuclei
in human lymphocyte cultures, indicating an association with genomic instability (Fenech
M. 2007). Most importantly, the results of some studies suggest the role of folate deficiency
in developing depression (Coppen and Bolander-Gouaille. 2005). Increasing evidence also
links folate levels with inflammation (Mangoni A. 2006). Due to the role of folate in
affecting methylation, gene expression and genomic instability, and its link with
inflammation and depression, it is important to consider it in the complete final analysis of
this study (part of full study; results reported elsewhere).
Baseline “germline” or heritable genetic background influences could also affect a
woman’s susceptibility to develop PN symptoms following treatment for BC. Background
genetic influences involve the genomic sequence with its gene mutations, including those
that might influence DNA repair mechanisms. In addition to germline genetic influences,
acquired genetic changes could contribute to differential outcomes for women with BC.
For example, tumor mutations, as well as baseline epigenetic modifications and
6

chromosomal instability levels, could play a role in a patient’s health outcome. Therefore,
both environmental factors and genetic background can lead not only to the development
of BC, but also to the susceptibility of a woman to develop inflammation and,
consequently, PN symptoms. For example, one mechanism where both genetic and
environmental factors could be integrated is through the regulation of a methylation site
overlapping with a single nucleotide polymorphism (SNP) that is associated with the
development of a phenotype (Taqi MM et al. 2011).

Breast Cancer:
BC is characterized by its heterogeneity and is highly challenging when it comes to its
classification and treatments decisions (Polyak K. 2011). Genetic and epigenetic research
has helped in improving the ability to understand the development of BC, its classification,
treatment decision and its prognosis.

BC classification:
BC has traditionally been classified clinically and histopathologically (Westbrook and
Stearns 2013, Viale G 2012). The tumor node metastasis (TNM) stage and tumor grade,
along with the histopathological classification, remain included in the report and have been
implicated in the prognosis of BC (Viale G 2012). BC has also been subdivided by
immunohistochemistry and/or fluorescence in situ hybridization (FISH) characterization
according to the presence or absence of the human epidermal growth factor receptor-2
7

(HER2), estrogen (ER), and progesterone (PR) receptors. The results of gene expression
microarray analyses have assisted in subdividing BC tumors into the molecular intrinsic
subgroups (Basal like, Luminal subtypes, HER-2 enriched, and normal like) (Perou et al
2000, Sorlie et al 2001, Sorlie et al 2003). The presence or absence of each of the three
receptors helped in refining the molecular subtypes as; luminal A (ER+ and/or PR+; HER2), Luminal B (ER+ and/or PR+; HER2+), basal-like (ER-, PR-, and HER2-) , and HER2enriched (ER-, PR-, and HER2+)(Sinn P et al. 2013, Byler et al. 2014). The later
classification has been extremely useful in directing the treatment and the prognosis of the
cancer (Byler et al 2014). However, the hormone responsiveness doesn’t always determine
the gene expression molecular subtypes. Many other genetic factors have been evaluated,
underscoring the complexity of the tumors and the difficulties in accurately identifying the
subtypes. In addition to the receptors noted above, BC tumors have been evaluated for
different gene mutations, frequencies of mutations and also different types of mutations
(non-sense or frame shift)(Byler et al. 2014). The heterogeneity and complexity when
classifying BC is due to the tremendous number of genetic changes that could be implicated
in its development. These changes include somatic gene mutations, copy number
variations, alterations in gene expression and epigenetic changes. In Table 1 a summary is
presented of some of the genes that have been found to show mutations or copy number
aberrations in BC.

The oncotype DX, and MammaTyper, are some of the currently available tools specific
for gene expression markers that were developed to aid in diagnosis, prognosis and therapy
decisions relating to BC (Sinn et al. 2013). However, due to the inherent instability of
8

mRNA, which makes its use challenging, there is a need for more stable and reproducible
tools. DNA methylation is an alternative tool. The stability and accessibility of DNA makes
it a more attractive target, especially if whole blood cells could be used rather than the
tumor tissue itself. Methylation will be more extensively discussed in the DNA methylation
section.

Treatment:
As more knowledge is being gained, there is a constant evolution of therapies given to
patients with BC. Treatments include hormonal therapies, targeted biologic therapy,
cytotoxic chemotherapy, and radiotherapy (Westbrook and Stearns 2013).

Hormonal Therapies:
Several hormonal therapies are available and approved for treating BC. The selective
estrogen receptor modulators (SERMs) -such as tamoxifen and raloxifene, and the third
generation aromatase inhibitors (AIs), including anastrazole, exemestane and letrozole, are
two classes of drugs commonly given to patients with BC (Westbrook and Stearns 2013).
Tamoxifen is the most widely prescribed SERM given to women with early stage hormone
responsive BC (Westbrook and Stearns 2013). It is also effective in treating women with
metastatic hormone receptor-positive BC and women having ductal carcinoma in situ
(Rose & Mouridsen, 1984, Cuzick et al 2002, Westbrook and Stearns 2013).
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Targeted biologic therapy:
Trastuzumab is one example of a targeted biologic therapy. This drug is a humanized
monoclonal antibody (HMAB) given to suppress cell proliferation caused by the
overexpression of the HER2 protein. It works by binding specifically to the HER2 receptor
(Westbrook and Stearns 2013). It is given in combination with chemotherapy and has led
to a significant improvement for treating HER2 overexpressing tumors and a significant
reduction in recurrence and mortality for women having this type of tumor (PiccartGebhart et a 2005, Romond et al 2005, Slamon et al 2011, Westbrook and Stearns 2013).

Trastuzumab is not the only drug that targets HER2+ tumors. Pertuzumab also has been
approved to be used in treating HER-2 + metastatic BCs by the European Medicine Agency
in 2013 (Sabatier & Goncalves 2014). It could be used in combination with Trastuzumab
and docetaxel. Moreover, lapatinib, which is a dual tyrosin kinase inhibitor could also be
used in targeting both EGFR and HER2 (Zhu et al 2013).

Another example of a targeted therapy is Bevacizumab, which is HMAB that targets
the vascular endothelial growth factor A (VEGF-A). (Westbrook and Stearns et al 2013).

Cytotoxic Chemotherapy:
The following are some of the cytotoxic drugs most often given to patients with BC.
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Antimicrotubules Agents:
Taxanes, including paclitaxel (Taxol) and docetaxel, are very effective chemotherapeutic
treatments given to patients with both adjuvant and metastatic BC. They cause cell death
by disrupting microtubule depolymerization and spindle formation during cell replication
(Westbrook and Stearns 2013).

Anthracyclines:
Both doxorubicin and epirubicin are anthracyclins that have been widely used in treating
BC. Although doxorubicin is widely used, the mechanism(s) for its effectiveness in
preventing/reducing cancer cell proliferation is/are not fully known, with some
investigators proposing that it induces cell apoptosis by inhibiting topoisomerase II, while
others cite roles for DNA adduct formation, oxidative stress, ceramide overproduction
and/or torsion-induced nucleosome destabilization as the causal means for this drug’s
efficacy (Gewirtz 1999; Senchenkov , et al., 2001; Minotti, et al., 2004; Yang, et al., 2014,
Westbrook and Stearns 2013).

Cyclophosphamide:
Cyclophosphamide is considered a backbone in BC treatment, which is incorporated
into many adjuvant BC chemotherapeutic drugs. (Westbrook and Stearns 2013)
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Carboplatin:
Is a platinium analog, which induce double stranded DNA breaks. It has shown more
efficacy in treating BRCA1- mutated tumors and triple negative breast cancers (Sikov et
al 2014)

Outcome:
Interestingly, patients treated with equivalent drugs show a significant variability in
response and in survival outcomes (Polyak et al 2011, Westbrook and Stearns 2013). While
the survival rate has improved significantly during the last few decades, it is time now to
consider the quality of women’s life after surviving BC, along with improving their
survival chances. One of our goals in this study is to understand how different types of
treatments are affecting patients’ methylation patterns or causing chromosomal instability
and how these latter changes relate to the acquired PNS affecting the patient’s quality of
life.

There is a need for a discovery of tools that can be used in biomonitoring a patient’s
response to a therapy (including its efficacy and toxicity) influenced by their genetic
makeup. Advances in the genetic technology allowed the identification of candidate genes
and SNPs that might associate with BC outcome. Some studies have been conducted with
the goal of identifying drug targets. Table 2 summarizes some of the candidate genes that
are thought to be associated with the outcome when a patient is treated with a specific drug.
While results from some studies support the associations between these genes and a
patient’s response to treatment, others failed to confirm an association. Thus, insufficient
12

evidence is available to allow for unequivocal recognition of these associations on health
outcomes in women treated for BC.

Epigenetic modifications:
Epigenetics refers to the mitotically heritable modifications in gene expression and
phenotype that do not involve any changes in the underlying DNA sequence (Russo et al
1996). Epigenetic information is important for normal mammalian development and in cell
differentiation (Reik 2007). It is not only involved in controlling gene expression, but also
in the formation of heterochromatin, which can play an essential role in chromosome
segregation and chromosomal stability (Herrera 2008). Feinberg et al, 2008, suggested
epigenetics as a link between environment, genetic background, and disease. Rapidly
growing evidence shows the major role of epigenetics in inflammation, developing cancers
and psychiatric diseases (Wierda et al 2010, Kristensen et al 2009, Pidsley and Mill 2011).
This process includes DNA methylation, histone modification, chromatin structure, and
noncoding RNA-mediated regulation of gene expression (Kouzarides 2007)). Among these
processes, DNA methylation and histone modifications are the most understood.

DNA methylation:
DNA methylation involves the addition of a methyl group to position 5 of the cytosine
pyrimidine ring (C) of a cytosine guanine dinucleotide (CpG) (Klose and Bird 2006). This
process is catalyzed by the DNA methyltransferase (DNMT) enzymes (Klose and Bird
13

2006). DNA methylation is one of the most stable and well-characterized epigenetic
mechanisms, which makes it an attractive area to focus on in our study (Jirtle and Skinner
2007). Typically, in normal cells, promoter CpG islands are hypomethylated while
repetitive DNA sequences in the genome are hypermethylated. Studies of genome-wide
DNA methylation in cancer cells revealed that the methylation patterns can be reversed
(Feinberg et al 2006). DNA methylation patterns in different tissues (normal and
cancerous) including blood, are known to be sensitive to environmental insults such as age,
alcohol intake and smoking (Table 3).

Genetic and epigenetic research has been very helpful in clarifying and understanding
the development of cancer/BC (Tables 1, 4-6). Most of the genetic research has been
performed using breast tumor tissues after the development of BC for purposes of
classification, treatment decisions and prognosis prediction. Epigenomic research in cancer
is a relatively new field. Studies of the role of epigenetics in cancer were initiated by
searching for candidate genes that are known to be involved in breast and other tissues’
carcinogenesis using tumor tissues from patients with cancer. The recently available
whole-genome methylation techniques allowed investigators to look for more global
changes and search for epigenetic signatures that might add more information to the
existing classification, with a goal of finding a better assessment of prognosis. Some
current findings from DNA methylation studies on breast tissues from patients with BC are
summarized in Table 4.
Researching the tumor itself is necessary for classification and treatment decisions for
14

the management of BC. However, an alternative approach that might be more powerful for
evaluating a patient’s response to a treatment and to be able to more accurately predict
systemic PN symptom outcomes could be through the study of peripheral blood specimens.
Studies of methylation patterns in blood samples, especially circulating cell free DNA
found in the serum or plasma, has been conducted with the purpose of finding biomarkers
for breast cancer risk and diagnosis, or for prediction of treatment outcome and prognosis.
DNA methylation patterns specific for cancer were found in the circulating cell-free DNA,
which is released from dead cancer cells (Sidransky 2002, Van De Voorde et al 2012).
DNA methylation biomarkers of BC found in the serum or plasma have been extensively
reviewed by Van De Voorde et al. (2012). A summation of these findings is presented in
Table 5. Panels composed of two, three or more biomarkers have been developed (Van De
Voorde et al 2012). It is important to note that methylation of many of these genes
identified as biomarkers are not specific for BC and could be found in other types of tumors
(Table 5). Problems of studying cell free DNA found in serum/plasma include the limited
amount of DNA present, requiring the use of very sensitive techniques; possible
contamination with DNA from whole blood cells; and limitations in following up acquired
changes in methylation patterns associated with the treatment after the surgical removal of
the tumor, since this cell free DNA is released from dead cancer cells.

Few studies have been done to investigate the association between BC -or cancer in
general- and DNA methylation patterns in peripheral blood cells (PBCs). The limited
numbers of studies using PBCs reflects concerns regarding whether the methylation
patterns in PBCs are suitable as a surrogate for changes arising in other tissues.
15

Investigators evaluated DNA methylation levels in PBCs of specific candidate genes as
well as global genomic levels. Based on the limited number of available studies, global
hypomethylation in PBCs has been associated with the presence of BC (Choi et al 2009).
Also, methylation of specific loci have shown promise for use as markers for the presence
of BC or an increased risk for developing BC (Iwamoto et al 2011, Wong et al 2010,
Brennan et al 2012, Widschwendter et al 2008). Fewer studies have been performed to
monitor chemotherapy effects on methylation of PBCs. Available data support the
hypothesis that PBCs are a good representative cell for evaluation and could be used as a
biomarkers indicating an increased risk for developing cancer, the presence of cancer, or
changes acquired as a result of cancer (Table 6).

Cancer is a systemic disease involving many tissues (including peripheral tissues) rather
than just the tumor by itself. It becomes even more systemic when patients are treated for
cancer, since all their tissues are exposed to cyto/genotoxic regimens that are mainly toxic
to the tumor, but also toxic to tissues within the human body as a whole. There are limited
numbers of studies investigating the effect of treatments on methylation patterns in PBCs
from patients with cancer.

The importance for using blood samples comes from the

accessibility of blood, the non-invasive means for collection, and the ability to detect risk
and follow-up acquired changes in methylation patterns longitudinally, allowing for
biomonitoring progression and changes associated with specific treatments for prediction
of outcome. Tumor tissues are not obtainable until after the development of the cancer and
it is not possible to follow up changes in the tumor tissue after its surgical removal.
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Chromosomal instability:

Micronuclei (MN) frequencies are widely used as an indicator of chromosomal
instability. Studies in our lab and other labs showed that high frequencies of MN associate
with aging, environmental exposures, and cancer (Table 7) (Fenech and Morley 1986,
Fenech and Morley 1985, Jones et al. 2011). MNs are thought to form as a result of
chromosome lagging at anaphase. They contain either whole chromosomes or
chromosomal fragments that are not incorporated in the daughter nuclei at the completion
of mitosis (Leach and Jackson-Cook 2001). Increased chromosomal instability has been
observed in tumor tissues, peripheral blood of patients with cancer, and following the
exposure of cells to chemotherapy and ionizing radiation (Table 7). Investigators have
shown that cells with increased levels of methylation alterations are more susceptible to
chromosomal instability (Herrera et al 2008). It has also been suggested that global DNA
hypomethylation could lead to chromosomal instability, aneuploidy, and contribute to
alterations in chromatin structure and cancer progression (Ulrich et al 2012).
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Table 1: Summary of a subset of genes implicated in the development of BC:
Type of genomic changes

Genes

References

Somatic gene mutations:
Well established genes in BC development:
Genes Involved in apoptosis, cell cycle regulation, and transcription regulation:
BRCA1 , RB1, TP53, PTEN, AKT1, CDH1, GATA3, PIK3CA

Stephens et al 2012 *

Genes Involved in Signal transduction:
APC, ARID1A, ARID2, ASXL1, BAP1, KRAS, MAP2K4, MLL2, MLL3, NF1, SETD2, SF3B1, SMAD4, AND STK11
A recently identified group of genes:
ARIDIB, CASP8, MAP3K13, MAPK2K13, NCOR1, SMARCD1, and CDKN1B

Well established genes in BC:
RB1, TP53, PTEN, AKT1, CDH1, GATA3, PIK3CA, MLL3, MAP3K1, CDKN1B
Mutation in 3 genes occur in > 10% incidence across all BC:

The Cancer Genome Atlas 2012*

TP53, PIK3CA, and GATA3
Novel genes:
TBX3, RUNX1, CBFB, AFF2, PIK3R1, PTPN22, PTPRD, NF1, SF3B1, and CCND3

Copy number aberration:
Amplification of regions containing PIK3CA, EGFR, FOXA1, and HER2 correlated with different mRNA subtypes

The Cancer Genome Atlas 2012 *

Deletion of regions containing MLL2, PTEN , RB1, and, MAP2K4 correlated with different mRNA subtypes

Used the MIP probe and identified 19 CNI that discriminate recurrence risk among early stage BC
The data suggest that specific CNI might promote or limit tumor spread in some cases
* Reviewed by Byler et al 201
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Thompson et al 2011

Table 2: Summary of candidate genes potentially related to BC outcome in response to a treatment*
Agent

Proposed Outcome

Candidate Variant Genes

Poorer outcome

CYP2D6 poor metabolizers, SULT1A1, UGT2B15, ABCB1, ESR1

Increased likelihood of tamoxifen discontinuation

CYP2D6 extensive metabolizers

Decreased hot flashes

ESR2

Better outcome

Fc gamma RIIIa-158V/V

Antimicrotubules: Docetaxel

Increased myelosuppression

SLCO1B3

Anthracyclines: Doxorubicin

Better outcome

ABCB1 C354T, MPO, NOS

Greater reduction of tumor burden , increased neutropenia

CBR311A

Better outcome

CYP2B6

Poorer outcome

ALDH1A1

Poor pathological CR, reduced risk of hematologic toxicity

GSTP1

Hormonal Therapy:
Tamoxifen

Targeted biologic therapy:
Trastuzumab
Cytotoxic chemotherapy:

Cyclophosphamide

*Adapted from review by Westbrook et al., 2013
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Table 3: Examples of environmental influences on DNA methylation in blood and other tissues in health and disease
Environmental influences

Tissue

Tool(s) used for assessment

WBC, Lung & other

Aging

solid tissues

Illumina Infinium 27k

(normal and cancer)

Goldengate assay

Finding
Found age-dependent DNA methylation signatures
of genes in WBC and in other tissues and were
independent of disease state, sex, tissue and cell
type.

References

Teschendorff
et al 2010

The signature is present in preneoplastic conditions
and might be associated with carcinogenesis

Cervix, mesenchymal stem
cells and ovarian cancer

Aging

WBC, CD4+ T cells, CD14+

Illumina Infinium 27k

Identified aging aDMRs signatures with a
multitissue phenomenon.

Rakyan et al 2010

GoldenGate

BC DNA methylation profiles are associated with

Christensen et al

monocytes, buccal cells

Alcohol intake, folate

BC tumor

and tumor size

Alcohol intake

alcohol & folate intake

WBC

LC-ESI-MS/MS for 5-mdC
Pyrosequencing for LINE-1

Smoking

WBCs

Illumina Infinium 27k,
Mass spectrometry
& Sequenom EpiTYPER

Associated differentially methylated regions (aDMRs)
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Among controls alone or combined with cases of
BC, alcohol
intake was inversely associated methylation levels

Identified a single locus (F2RL3) differentially
methylated
between exposure groups
The gene was fully replicable in an independent
sample

2010

Choi et al 2009

Breitling et al
2011

Liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS)
Table 4: Methylation patterns in BC tissue tumor:
Tool(s)

Findings

References

Genome Atlas Network

BC can be classified into several groups that are related to the cellular origin of the tumor and
are different than current gene expression classification, with some overlap with intrinsic
subgroups

The cancer Genome Atlas 2012
(1)

MeDIP* (Familial BC)
Validation by pyrosequencing and
epityper

Studied familial BC and identified distinct profiles defined by mutation status

Flanagan et al 2010

Illumina 27 k

Methylation of 4 genes is affected by ER/PR status

Li et al 2010

(2)

Illumina 27 K

Identified a group of genes where their methylation is associated with relapse free survival

Hill et al 2011

(2)

Illumina 27 k

Identified a methylator phenotype that is associated with lower risk of metastasis and better
survival rate

Fang et al. 2011

(2)

Illumina Golden Gate methylation
Validation by Sequenom EpiTYPER

Identified a distinct subtype of BRCA tumors based on their methylation profile

Tumor grade, size, estrogen and progesterone receptor status, and triple negative are
associated with altered methylation
Association with race, and tumor size.

* Methylaed DNA immuneprecipitation (MeDIP)
(1) Reviewed by Byler et al 2014
(2) Reviewed in Szyf , 2012
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Christensen et al 2010

Table 5: Summary of biomarkers for BC based on studies of cell free DNA from serum/plasma*:
Type of Biomarkers

List of genes

Biomarkers related to BC:
Markers involved in cell cycle regulation

BRCA1, GSTP1, RASSFA, APC,RAR-β , MGMT, P16 INK4A , P14ARF , 14-3-3-σ, TMS1, Cyclin D2

Markers related to hormone receptor

ESR1, ESR2, PR

Markers involved in cell adhesion

CDH1, TIMP-3, Slit2

Biomarkers associated with poor prognosis

RASSF1A, APC , GSTP1, BRCA1, 14-3-3-σ, PITX2, P16INK4A, ERB, RARβ2,

Biomarkers for response to treatment
Surgery and Tamoxifin

Surgery significantly reduced the methylation of MGMT, PAX5, and RARB2, but not MDGI
Tamoxifen had a more pronounced effect on MDGI
Methylation of PR PROX was equally affected by surgery and tamoxifen
Methylation of ESR1 and MSH1 was initially reduced by surgery, but increased during tamoxifen treatment

Neoadjuvant chemotherapy

Methylation levels of RASSF1A in serum may indicate tumor shrinkage
could be used in monitoring response during neoadjuvant chemotherapy

Markers found in other types of tumor

Lung: BRCA1, APC, RAR-β, P16,
Ovarian: BRCA1, RASSF1A, Slit2
Liver:GSTP1, Hepatocellular cancer: Slit2
Prostate: GSTP1, RASSF1A, Slit2, ER
Bladder: RASSF1A,
Stomach: APC, Gastric cancer: CDH1, Gastrointestinal tract: P16, 14-3-3-σ,
Colorectal: APC
Glioblastoma: RAR-β, P14ARF, TIMP3, Glioma:MGMT, P16, Neuroblastoma: TMS1
Lymphoma: P16, Cyclin D2, Multiple myeloma: P16
Cervix: P14ARF
Cholangiocarcinoma: TMS1
Pancreas: TMS1
Melanoma: ER
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Endometrial: PR
* Adapted from reviewed by Van De Voorde et al., 2012
Table 6: Methylation biomarkers in WBCs for different types of cancer
Tissue/type of tumor

Tools

Finding

References

IGF2

PBL / (P&D CM)

Imprinting analysis

LOI at IGF2 in PBL could be a valuable predictive marker of risk for CRC

Cui et al 2003

IGFE

PBL

Quantitative hot-stop
PCR

LOI at IGFE in PBL as a hereditary risk factor for colon neoplasia

Cruz-Correa
et al 2004

Gene:

for imprinting analysis

49 genes *

WBCs/BC

MethylLight assay

DNA methylation in WBCs provides a good prediction of BC risk

Widschwendt
er et al 2008

BRCA1 promoter

WBCs/BC

Methylation specific
qPCR

BRCA1 promoter methylation in WBCs is significantly associated

Iwamoto et al
2011

with risk of BC tumors with BRCA1 promoter methylation

BRCA1

WBCs/BC

MethylLight and (MSHRM)

BRCA1 methylation in WBCs identifies a small group of women

Wong et al
2010

in the population who have increased risk for an early-onset BC
ATMmvp2a &
ATMmvp2b

WBCs

Bisulfite
pyrosequencing

/ LINE-1

DNA methylation at ATM could be a marker of BC

Brennan et al
2012

No differences in LINE-1 between cases and controls

Global:
WBCs/ BLC

Illumina 27k

DNA methylation profiles associate with risk of BLC

Marsit et al
2011

WBC/ BLC

HPCE & Hpa II D&D

Hypomethylation associate with increased risk of developing BLC

Moore et al
2008
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WBC/ (HNSCC)

Modified version of

DNA hypomethylation is associated with HNSCC,

CBRA of LRE1 sequence

Complex relationship with the known risk factors

Hsiung et al
2007

ex: smoking and folate intake

WBCs / PaC

GoldenGate (phase l) &
ICVC

DNA methylation signature that can detect (PaC)

Pedersen et al
2011

DNA methylation signature that can detect or predict risk of OC

Teschendorff
et al 2009

Global DNA hypomethylation is associated with development of BC

Choi et al
2009

MethylLight

DNA methylation levels in WBC from control girls are associated

Wu et al 2011

Pyrosequencing

with family history of BC

MethylLight

Sig. correlation in methylation of Sat2m1 between the 3 tissue types

(phase ll)

WBCs/ OC

WBCs /BC

WBCs/BC

Illumina 27k
(LC-ESI-MS/MS) for( 5mdC)
Pyrosequencing for(
LINE-1)

Sat2M1:
WBCS/BC tumor/ &
adj. normal tissue

Cho et al
2010

Sig. differences in methylation of Sat2M1 between cases and controls

LINE-1:
WBCs / RCC

Pyrosequencing in
triplicate,
& averaged across 4
CpG sites

High LINE-1 methylation levels were positively associated with RCC

Liao et al
2011

The association was stronger with current smokers than with
former / never smokers

Lymphocyte/BLC

Pyrosequencing

LINE-1 hypomethylation is associated with BLC risk among non-smokers
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Cash et al
2012

Reduced LINE-1 methylation in current smokers with high
cytochrome index

WBCs/ BLC

Pyrosequencing

Line-1 hypomethylation is associated with BLC risk;

Wilhelm et al
2010

especially among women

BC and
Chemotherapy

Blood Mononuclear cells

Illumina 450k

8 CpG sites were hypomethylated in women treated with chemo

Smith et al

as compared to control (not treated) women;

2014

After radiation only 4 CpG sites remained
Methylation at these sites was associated with inflammation but not with
fatigue
* Lymphocyte (PBL)
Quantitative analysis of methylated alleles (QAMA)
loss of imprinting (LOI)
Colorectal cancer (CRC)
49 GENES included a) 19 ERT genes b) 4 genes ER-a target genes(diffrentially methylated based on hromone receptor status) c)20 PCGT genesmore likely have a promoter DNA
hypermethylation in cancer . D) 6 genes that are known to be methylated in BC (MBC)
proximal and distal colonoic mucosal (P&D CM)
Head and neck squamous cell carcinoma (HNSCC)
Pancreatic adenocarcinoma (PaC)
Bladder Cancer (BLC)
Ovarian Cancer(OC)
Renal cell cancer(RCC)
Liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS)
Methylation Sensitive-High Resolution Melting (MS-HRM)
high-performance capillary electropheresis(HPCE)
combined bisulfite restriction analysis (CBRA)
digestion & densitometry (D &D)
Illumina. custom VeraCodemethylation (ICVC)
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Table 7: Summary of previous studies related to BC or its treatment evaluating MN frequencies in
peripheral blood lymphocytes
Topic
Breast Cancer Effects
Higher MN frequencies in untreated women with breast cancer irrespective of
smoking and aging

References
Santos et al.,
2010

Significant differences in MN frequencies at baseline between patients with breast
cancer and controls

Cardinale, et al.
2012

Chemotherapy Effects:
In vitro study showing variation in response to doxyrubicin-induced MN between
lymphocyte cell lines; Polymorphism in the GSTP1 gene was associated with an
increased MN frequency

Ramos et al.,
2011

In vitro study showing a significant increase in MN frequencies in breast cancer cell
lines following exposure to doxyrubicin; methoxyamine alone did not significantly
increase MN frequencies; use of both methoxyamine and doxorubicin significantly
increased levels of MN frequencies (combination higher than single exposure values)

Guerreiro et al.,
2013

In vivo study showing MN frequencies in lymphocytes and buccal mucosa cells from
children with malignant tumors (various types) increased significantly following
chemotherapy
In vivo longitudinal study (1 year) showing MN frequencies increased significantly
after one cycle of chemotherapy and remained increased for 2 months after the
completion of chemotherapy (Cisplatin); MN frequencies also correlated with the
cumulative dose of Cisplatin and with Cisplatin-induced nephrotoxicity
Radiation Effects:
In vivo study showing MN frequencies increased significantly during radiation and
further increased immediately following the completion of radiation; MN frequencies
not influenced by age
Higher MN frequencies during radiotherapy; while decreases in frequency were
observed 6 months and one year after radiotherapy, MN frequencies did not return to
pre-therapy level in the majority of patients; older subjects (ages 75-80; also had
more advanced tumors) showed higher MN frequencies than younger subjects (ages
57-70)
In vivo studies showing radiation-induced MN frequencies were correlated with dose
and quality of occupational, medical, accidental, or therapy-related radiation
In vitro study showing significant increase in MN frequencies in cells exposed to
ionizing radiation, with the difference in frequency responses of patients with breast
cancer compared to controls exceeding the differences observed at baseline
Chemotherapy and Radiation Effects:
In vivo study showing an increased frequency following radiation alone and following
radiation in combination with chemotherapy regardless of age or smoking

Minicucci et al .,
2008
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Elsendoorn et al
2001

Jagetia et al.,
2001
Gamulin et al.,
2010

Vral et al., 2011
Cardinale, et al.,
2012

MilosevicDjordjevic et al.,
2011

In vivo longitudinal study (18 months) showing MN frequencies increased after
radiation (20 patients received radiation) but not after chemotherapy (only 9 out of
20 patients received and were assessed after chemotherapy)
MN frequencies were not significantly correlated with tumor size, receptor status,
nodal status, family history of cancer, age, or smoking habits
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Aristei et al.,
2009

Hypothesis, goals, aims, study design and significance of the present study:
Hypothesis:
Treatment advances have resulted in improvements in survival for women diagnosed with
breast cancer, but many of these survivors report acquiring persistent adverse side effects
following treatment. The etiology of the observed PNS is not fully known. Chemotherapy, or the
tumor itself, induces short-term effects and long-term PN effects through a series of events and
interactions, which result in acute and chronic biologic changes, where some could be persistent
for years after completing a successful treatment. We offer the hypothesis that inflammatory
activation is an early step in a cascade of biological changes leading to genomic and/or epigenetic
alterations that contribute to PNS. Alternatively, epigenetic alterations may occur first, leading to
inflammatory activation. These epigenetic changes could also lead to chromosomal instability.
Each of these genomic/epigenetic factors, acting either singly or in concert, could contribute to the
development/persistence of PNS since they would provide a means for “remembering” the
biological effects after chemotherapy and have plasticity to explain responsiveness to
environmental exposures (as well as G x E interactions). They also have the potential for
reversibility, with the latter attribute being important for the potential development of therapeutic
interventions (Figures 1 & 2).
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(A)

Goal:
Investigate the biological basis for the development of the clustering PNS associated with
chemotherapy, or the cancer itself, in women treated for BC.

Specific aims:
The primary aims of this study were to collect blood specimens from women having a diagnosis
of BC and longitudinally determine:
1) The frequency of acquired chromosomal instability and genome wide methylation changes
present at baseline and following treatments.
2) The relationship between acquired chromosomal alterations and the development of PNS.

Overall study design: (Note: This thesis is a part of a larger study design)
In order to understand the epigenetic and the chromosomal instability changes, and their role
in developing PNS, which are associated with BC and its treatments, we designed a longitudinal
study to follow a total of 76 women treated for BC at 5 time points within a two-year time period.
For the facet of the study reported in this thesis, acquired changes in PBCs methylation patterns
and frequencies of MN formation in binucleated lymphocytes were examined at 4 time points:
before the initiation of chemotherapy, at the 4th chemotherapy, 6 months after the initiation of
chemotherapy (at which time some women are receiving radiation therapy), and 12 months after
30

the initiation of chemotherapy. Because it is not completely clear whether the tumor itself or the
treatment is initiating the development of these symptoms, we initiated copy number assessments
in tumor tissues obtained from a subset of women who provided their consent to have their tumor
specimens evaluated.

The tissue sample choice:
In order to identify acquired epigenetic changes/chromosomal instability associated with the
development of PN symptoms observed in a subset of women treated for BC, one would think of
the brain tissue as one of the most affected or permanently affected tissues. While acquired
epigenetic changes in brain cells are likely to be associated with some of the observed symptoms,
such as cognitive dysfunction, they would not be anticipated to be clearly associated with all of
the observed symptoms, such as fatigue. Also, it is not possible to sample brain tissue from living
individuals (especially since multiple brain areas would need to be evaluated to most accurately
reflect the neural tissue changes that might arise).

Inflammation, which results from BC, and its treatment, has been suggested to have a role in
PNS production (Konsman et al 2002, Lee et al 2004, Cleeland et al 2003). Because white blood
cells (WBCs) are involved in the inflammatory process, blood samples are optimal. As mentioned
earlier, animal models, preclinical and clinical evidence showed that sickness behavior requires an
immune-to-brain communication, which involves cytokines and (WBCs) (Cleeland et al 2003).
Therefore, we believe that blood samples are one of the best sample choices to be investigated in
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our study. Moreover, we are investigating acquired changes associated with chemotherapy. Thus,
blood cells are one of the first cells to be exposed and affected by the therapy. Indeed, leukocytes
could reflect one of the earliest acquired epigenetic changes associated with BC chemotherapy and
inflammatory induction, which happen before triggering other changes that cause the occurrence
of the permanent changes in brain cells. Blood samples are easily obtained and all parts of our
study could be easily performed on this type of tissue, including inflammatory biomarkers
measurement, acquired epigenetic changes, gene expression and MN frequencies assessments.
Furthermore, for future implications, if epigenetic signatures or MN assessments could be used to
estimate an individual’s risk or could be treated, this sample will be the easiest to obtain and follow
up.

Another sample that would be interesting to look at is cells from the tumor cells themselves.
The tumor may be the source that initiates a cascade of changes, including inflammation, and
acquired epigenetic changes in other tissues such as WBCs. Cytokines could be produced not only
by immune cells, but also by other cell types such as the tumor cells in cancer patients (Cleeland
et al 2003). It remains unclear how chemotherapy affects women and associates with the
development of PNS in a subgroup of women treated for BC. Thus, it is important to investigate
not only blood samples, but also the tumor tissue itself. It is possible that the tumor cells define or
are related to the susceptibility of women to develop PNS as a result of chemotherapy.
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Significance:
The results from this study will enable us to gain a better understanding of the biological basis
for the development and persistence of PN symptom in women with BC, with the hope of
enhancing the quality of survivors’ lives. With advances in the pharmacology of epigenetics, if the
development of PN symptoms could potentially be detected at an earlier point, they might be
prevented or alleviated through treatment. Alternatively, the results of this study could provide a
basis for recognizing women who are most “at risk” for developing PNS, thereby allowing them
to make more informed decisions regarding their therapy options. This study is the first of its kind
where multiple biological mechanisms and symptom assessments are followed during the
treatment course with a hope of helping BC survivors to live with a better quality of life.
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Chapter 2

Acquired Chromosomal Changes in Women Treated for Breast Cancer and their
Association with the Development of Psychoneurological Symptoms
Micronucleus frequencies in lymphocytes

Introduction
Breast cancer is the most common invasive cancer in females, accounting for approximately
29% of all women’s cancers (Siegel et al, 2014). According to estimates from the American
Cancer Society, about 12.3% of women in the US will develop breast cancer during their lifetime
(American Cancer Society, 2013). Due to advances in early detection and management,
approximately 89% of women diagnosed with breast cancer will survive for at least 5 years
(American Cancer Society, 2013). Unfortunately, these advances in survivorship have been
accompanied by the acquisition of treatment-related adverse side effects that can compromise the
quality of life for many women who receive treatment for breast cancer. These side effects,
which include anxiety (Badger et al. 2007), depression (Badger et al. 2007), fatigue (Berger et al.
2010), cognitive dysfunction (Wefel et al 2011) , sleep disturbance (Lee et al 2004), and pain
(Utne et al 2010, Valeberg et al 2008), are collectively referred to as psychoneurological
symptoms (PNS) and can persist for years after treatment.

The biological basis for the genesis of PNS in women treated for breast cancer is not known.
The results of some cross sectional studies have shown an association between markers of
inflammation, most notably proinflammatory cytokines, and PNS (Cleeland et al 2003, Fumaz et
al 2012). However, investigators have not attained a clear consensus regarding the etiological role,

34

if any, of cytokines in chemotherapy-related PNS (Dantzer et al 2001, Cleeland et al 2003, Lee et
al 2004). More recently, conjectures about the biological basis underlying the development and
persistence of chemotherapy-related PNS have shifted to include mechanisms that would account
for both the short-term presentation of symptoms, as well alterations that could be biologically
“remembered” or retained for months/years. One potential means whereby chemotherapy could
induce the development and persistence of PNS is if that therapy resulted in the acquisition of
somatic chromosomal instability. This soma-wide instability could result in the development of a
clonal population(s) of cells having a chromosomal imbalance, which, in turn, could lead to the
development of PNS and/or other health conditions. Recent advances in methodology support the
premise that somatic mosaicism and/or mutations are associated with a variety of health conditions
(Grayson, et al., 2010; Forsberg, et al, 2013; Poduri, et al., 2013; Li, et al., 2014). In particular,
spontaneous somatic chromosomal instability/mosaicism has been associated with the
development of cancer (Santos et al . 2009, Cardinale et al , 2012, Chang et al. 2010); dyskeratosis
congenital (Jongmans, et al., 2012); rheumatoid arthritis (Tascioglu et al., 2005); and osteoarthritis
(Castellanos et al. 2004, Dahlen et al., 2001, Kinne et al., 2001, Mertens et al., 1996, Broberg et
al., 1998). Somatic chromosomal mosaicism has also been associated with several conditions
involving behavior and/or cognition, including but not limited to, Alzheimer’s disease
(Zekanowski and Wojda 2009; Yurov, et al., 2013), Parkinson disease (Migliore et al 2001), agerelated cognitive decline (Faggioli, et al., 2011), schizophrenia (Yurov, et al., 2013; Ruderfer, et
al., 2013), and stressful events (York, et al., 2013).

Chromosomal instability has been observed by several investigators in cells from breast cancer
tumors (Yoon et al 2003, A’Hern et al 2013, Burell et al 2010 , Kabalar et al 2012, Niu et al 2013,
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Ottesen et al 2003, Jiang et al 2014), as well as in cells from peripheral tissues (typically blood) of
people diagnosed with cancer prior to their receipt of treatment (Santos et al 2010, MilosevicDjordjevic et al 2010, Harsimran et al 2009). While few in number, studies have also been
completed to evaluate the frequency of chromosomal instability in peripheral blood following
exposure to various treatments for breast cancer, with these reports noting an increase in
chromosomal instability values soon after radiation treatment (Jagetia et al 2001; Gamulin et al
2010; Vral et al 2011; Cardinale et al 2012) or radiation and chemotherapy (Aristei et al 2009;
Milosevic-Djordjevic et al 2011).
Given that chromosomal instability appears likely to arise after treatment for breast cancer, it
follows that these chromosomal aberrations might result in somatic mosaicism that could
compromise the function of the cells containing these aberrations. Based on this premise, we
hypothesized that an increase in micronuclei frequencies arises following chemotherapy and that
this increase in somatic chromosomal instability is associated with the development and/or
persistence of PNS in women receiving therapy for breast cancer. To test this hypothesis we
designed a 2-year longitudinal study to determine the frequency and retention of acquired
chromosomal changes in women diagnosed and treated for breast cancer. This current study
reports the findings from one year of follow-up for this longitudinal study. The time points
evaluated include: baseline (before the initiation of chemotherapy); mid-cycle (typically at the 4th
chemotherapy treatment); 6 months following the initiation of chemotherapy (at which time a
subset of women have recently received radiation therapy); and 1 year following the initiation of
chemotherapy.
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Materials & Methods

Study Participant Ascertainment and Specimen Collection
A total of 76 women with early stage (I to IIIA) breast cancer, who ranged in age from 23 to
71 years old, were ascertained through 5 regional cancer centers in Central Virginia. To identify
potential study participants, a member of the research team attended the weekly interdisciplinary
Breast Health meetings that were held at the Virginia Commonwealth University Medical Center
(VCUMC). Study eligibility criteria for participants were: (1) 21 years or older; (2) diagnosis of
early stage breast cancer with a scheduled visit to receive chemotherapy; and (3) female (males
were excluded since too few male participants were available for study). Exclusion criteria
included: (1) a history of previous cancer, or chemotherapy; (2) a diagnosis of dementia; (3) active
psychosis; or (4) a history of immune-related diagnoses (e. g. multiple sclerosis; systemic lupus
erythematosus). After providing informed consent (VCU IRB #HM 13194), participants were
enrolled and the first study visit was scheduled prior to the initiation of chemotherapy. Study visits
took approximately one hour to complete. A peripheral blood sample was collected at each of the
4 time points by venipuncture or through an existing access device and transported (same day) to
our (Jackson-Cook) cytogenetics laboratory. The specimens were coded prior to their delivery to
the lab to ensure that the cytogeneticists were unaware of the clinical history and PNS status of
each participant at the time of sample processing and evaluation.

37

Demographic, Lifestyle, Breast Tumor and Other Health Information

Demographic information for the study participants was collected by self-report using a
questionnaire format. Demographic variables evaluated in this current report included age, race,
and income. Similarly, lifestyle factors [nutritional practices (eating vegetables/fruit); smoking
status, and ethanol usage] and health attributes not directly related to the diagnosis of breast cancer
[menopausal status (pre- or post-)] that were evaluated in this 1 year follow-up report were
obtained from self-report. Medical records were used to determine body mass index, breast tumor
attributes, and chemotherapy regimens. Based on the tumor fluorescent in situ hybridization
(FISH) and/or immunohistochemical testing results, which were obtained from the medical
records, the tumors were categorized as luminal A (human epidermal growth factor receptor 2
[HER2] -; estrogen receptor and/or progesterone receptor +), luminal B (HER2+; estrogen receptor
and/or progesterone receptor +), HER2 positive (HER2+; estrogen receptor -; progesterone
receptor -), or triple negative (HER2-; estrogen receptor - ; progesterone receptor -) (Perou, et al.,
2000; Hu, et al., 2006, Fan, et al., 2006; Voduc, et al., 2010; Carey, et al., 2013).

Chemotherapy and Radiation Treatments
The chemotherapy treatments received for study participants were determined by medical
record review. Three primary types of chemotherapy administered included: (1) taxotere
(docetaxel), adriamycin (doxorubicin), and cyclophsophamide [TAC]; (2) taxotere and
cyclophosphamide [TC]; or (3) taxotere (docetaxel), carboplatin (paraplatin); and herceptin
(transtuzumab) [TCH]. The recognition of each participants’ receipt of radiation therapy (or lack
thereof) was also derived from reviews of the medical records. All blood specimens were collected
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within 1 month after treatment, with most chemotherapy specimens being collected within 2 weeks
of exposure.

Chromosome Instability Methodology
Chromosomal instability levels were quantified for each specimen using the cytokinesis-block
micronucleus (CBMN) and cytome assay (Fenech, 2006). A micronucleus (micronuclei) (MN) is
(are) small chromatin containing structure(s) juxtaposed to a parent nucleus (Figure 3). The CBMN
assay was selected for the chromosomal instability assessments because it allows for: (1) the
quantification of both numerical and structural cytogenetic findings; (2) the analysis of a large
number of cells, thereby enhancing one’s ability to detect even low levels of instability; and (3)
minimization of in vitro growth selection (only 1 round of cell division is completed in vitro) and
minimization of technical artifacts due to processing (for example, the CBMN assay does not show
chromosome “loss” due to cell breakage at harvesting or slide making, which can occur when
assessing metaphase chromosomes).

Leukocytes, which were isolated using Histopaque-1077 (Sigma), were established in culture
according to the protocol of Fenech (1993). Briefly, following their mitogenic stimulation using
phytohemaglutinin (PHA), lymphocytes were arrested at cytokinesis by adding cytochalasin B to
the cells 44 hr after their culture initiation. The cells were harvested 72 hours after culture initiation
and slides prepared (2 per specimen) as described previously (Leach and Jackson-Cook, 2001)
(Figure 4)
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Micronuclei, buds, and/or bridges were visualized following giemsa staining (4% Harleco
Giemsa solution) and identified according to the criteria established by Fenech (2006). The
proportion of abnormalities was calculated by adding the values obtained from the two replicate
scores (1000 binucleates were evaluated from each of two slides for a total of 2000 binucleates per
study participant). The total number of binucleates with abnormalities was then divided by the
total number of binucleates scored.

PNS Assessment
PNS were assessed based on study participant self-reporting or computer interfaced
performance measures using well established biobehavioral tools. Briefly, cognitive dysfunction
was evaluated using the CNS Vital Signs (CNSVS, https://www.cnsvs.com) computerized
neurocognitive testing system, in which practice effects are minimized by randomly generated
alternate test forms or random selections from item banks (ref). Cognitive measures evaluated in
this study included the overall cognitive index, memory, complex attention, psychomotor speed
and cognitive flexibility domains. Depressive symptoms and anxiety were identified using the
hospital anxiety and depression scale (HADS), which is a brief (14-item) self-report questionnaire
that has well-established reliability and validity for both depressive symptoms and anxiety in
women with breast cancer. Fatigue symptoms were evaluated using the Brief Fatigue Inventory
(BFI), which is a clinically validated tool used to assess cancer-related fatigue and its impact on
daily functioning. Participant sleep disturbances were assessed through self-report using the 21item General Sleep Disturbance Scale (GSDS), which evaluates various aspects of sleep
disturbance (quality and quantity of sleep, sleep onset latency, number of awakenings, excessive
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daytime sleepiness, and medication use) over the past week. Pain was evaluated using the Brief
Pain Inventory (BPI), which assesses the severity and location of pain, pain medication use,
amount of pain relief in the past 24 hours or the past week, and the impact of pain on daily
functions. The arithmetic mean of the 4 severity items were used as a measure of pain severity,
and the arithmetic mean of the 7 interference items were used as a measure of pain interference.
Perceived stress was measured using the 10-item Perceived Stress Scale (PSS).

Statistical analysis
Descriptive statistics of MN/cytome frequencies were computed for the demographic,
tumor characteristic, treatments, and PNS symptoms variables noted above. All data were
examined graphically to determine their distributional properties. It was anticipated that the
MN/cytome frequencies would follow a log-normal distribution as is typical with MN frequency
data (Ceppi, et al., 2011).

However, because of the relatively high number of MN in this

population, the MN frequencies were approximately normally distributed.

Using the model building approach proposed by Hosmer and Lemeshow (2000), a mixed
effects linear model (Brown and Prescott, 2006) was fit (by R. K. Elswick, Jr.) to determine the
best subset of predictors of MN/cytome frequencies. In the first stage of the model building
process, a base model was selected that represented the design of the data collection and of the
timing of the treatments (chemotherapy and radiation). Fixed effects included time (baseline, midchemo, six months and 1 year post-chemo), chemotherapy (TAC, TC and TCH), time by
chemotherapy interaction (chemotherapy was administered only during time point 2), radiation
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(Yes/No); time by radiation interaction (radiation was only administered at time point 3), and a
random effect for study participant. In the second stage, each potential predictor was fit
individually with the base model and, if the p-value was 0.25 or less, that predictor was used in
the next stage. Potential predictors included demographic variables (age, race, BMI, income,
menopausal status, current smoking status & alcohol consumption, and lifestyle nutrition), tumor
characteristic variables (grade, stage. luminal A, luminal B, triple negative & HER 2 positive
status), surgery, PNS variables (HADS depression, HADS anxiety, BPI worst, BPI least, BPI
average, BPI now, BPI relief, BPI interference, BFI total, BFI now, BFI usual, BFI worst, BFI
interference, GSDS total, total PSS) and cognition variables (NCI, Memory, Complex attention,
Psychomotor speed & Cognitive flexibility). In the third stage, all potential regressors (p< 0.025)
were put into a multiple variable model. This initial model was further refined by sequentially
removing variables from the model with the highest p-values (backward stepwise) until all
remaining factors had a p-value of 0.05 or less. At this stage, all pairwise interactions were added.
Again using a backward stepwise approach, all interaction terms with p-values less than 0.05 were
removed. This model was considered the final prediction model. The SAS v9.2 and JMP v11.1
statistical packages were used for these analyses (SAS 9.3 and JMP 11.1: SAS Institute Inc., SAS
Campus Drive, Cary, North Carolina 27513.). In order to limit type I errors, an alpha level of
p<0.05 was used for all statistical tests.
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Figure 3: The appearance of a micronucleus (MN) juxtaposed to a binucleated
lymphocyte stained by Giemsa.
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Methods:

(A)

(B)

Figure 4: Description of the Cytokinesis Block MN (CBMN) assay. Briefly, the buffy caot
consisting of leukocytes was isolated using Histopaque. Following their mitogenic stimulation
using phytohemaglutinin (PHA), Lymphocytes were arrested at cytokinesis by adding
cytochalasin B to the cells 44 hr after their culture initiation. The cells were harvested 72 hours
after culture initiation and slides were prepared (2 per specimen), stained and scored.
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Figure from Illumina
Website

Results

A total of 73 of the 76 women initially recruited for this longitudinal study elected to complete
the first year of sample collections (96% retention rate), with 1 participant providing only a
baseline specimen (withdrew due to lack of time/interest); and 2 participants failing to provide
specimens for all 4 times (both women cited lack of time as their reason for not continuing). For
times 3 and 4, assessments were completed for 67 and 50 of the study participants, respectively,
with the smaller number of specimens evaluated for these times reflecting pending specimen
collections in this ongoing, 2-year longitudinal study. The majority of the women in this study
received a TAC chemotherapy regimen (n=39), followed by TC treatment (n=21), or TCH
treatment (n=11). Two of the women received a cyclophosphamide, methotrexate and 5
fluorouracil treatment (CMF). Given the small number of women receiving this treatment, this
group was excluded from the analysis. Thus, comparisons of factors influencing chromosomal
instability frequencies were completed for a total of 71 women.

Demographic data, tumor characteristics, and treatment information is/are shown for the 71
women fully participating in this longitudinal study in Tables 8-10. These participants included
22 women of African American heritage and 49 women of Caucasian heritage. Only 2 women (1
in the African American cohort and 1 in the Caucasian cohort) self-reported that they were of
Hispanic ethnicity. Thus, given the small number of women having a Hispanic heritage, this subgroup was not analyzed separately. Since none of the 14 women who reported smoking met the
criteria of a heavy smoker, as suggested by Fenech et al. (2006) for assessments of the influences
of smoking on micronuclei frequencies, smoking habits were not included in our statistical model.
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The average age of the study participants was 51.59 years, with a significant difference in age
being observed between the African American (mean= 47 years, s.e.=1.89 years) and Caucasian
(mean= 53 years, s. e. =1.46 years) sub-groups (p=0.006) (Table 8). Annualized income levels also
varied between the racial groups, with the Caucasian patients having significantly higher incomes
than the African American women (p<0.0001). As expected, the majority of women (56%) were
post-menopausal with 44% being either pre- or peri-menopausal (Table 8). No significant
difference in menopausal status was detected between the African American and Caucasian study
participants. However, significantly more Caucasian women reported consuming alcohol (69%)
than African American women (27%) (p=0.0016 ) (Table 8).

Due to the inclusion criteria established for this study, all of the study participants had early
stage breast cancer (stages I to IIIA). The participants’ clinical pathological characteristics and
their pre-chemotherapy treatments are summarized in Tables 9 and 10, respectively. While the
proportion of African American women having grade 3 (Grade 3 - 40.91%) tumors tended to be
lower than the proportion of Caucasian women (Grade 3 – 59.18%) these tumor distributions were
not significantly different (p=0.153). Similarly, while no significant difference in the proportion
of the 4 intrinsic subtypes of tumors was observed between the racial sub-groups (p=0.107), there
was a trend toward a higher proportion of triple negative tumors and a lower proportion of luminal
A tumors in the African American women (triple negative tumors-36.36%; luminal A tumors36.36%) compared to the Caucasian women (triple negative tumors-24.49%; luminal A tumors61.22%) (Table 9). As expected, due to the lack of a significant difference in the tumor
characteristics in the African American compared to Caucasian women, no significant differences
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were observed in the treatment regimens between the racial groups (chemotherapy p=0.2011;
radiation p=0.213).

To determine if any of the treatment, health, demographic, or symptom variables were
associated with MN/cytome abnormality frequencies, the data were fit to a mixed effects linear
model (Table 11). The final optimized model identified 8 variables that had a significant predictive
association with MN/cytome abnormality frequencies (Table 11). These variables included: (1)
the time point at which the specimen was collected (p<0.0001); (2) the type of chemotherapy
treatment (p=0.0463); (3) exposure to radiotherapy (p=0.0004); (4) race (p=0.0037); (5) having a
luminal B tumor categorization (p=0.0182); (6) having a triple negative tumor categorization
(p=0.0446); (7) total perceived stress (p=0.0123); and (8) cognitive flexibility domains
(p=0.0238).

The strongest significant association between MN/cytome abnormality frequencies was the
time at which the specimens were collected (p<0.0001) (Table 11 & Figure 5). Almost all women
showed a significant increase in their chromosomal instability frequencies at time point 2 (the midchemo specimen). Those participants who received radiation showed an additional increase in their
MN/cytome abnormality frequencies at time point 3 (figure 6). Interesting, while the chromosomal
instability frequencies were highest at times 2 and 3, the time 4 values (1 year following the
initiation of chemotherapy) tended to remain higher than baseline values (Table 11).

The frequency of MN/cytome abnormalities also differed based on the type of treatment the
participants received. The greatest increase in MN/cytome abnormality frequencies in response to
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the administration of chemotherapy (time point 2) was observed for the women who received TAC
treatment (Figure 5). However, the women who received TCH treatment had the highest overall
value of chromosomal instability (mean = .071, SE = .0042) when compared to women receiving
TAC (mean=.063 SE =.0043) or TC (mean=058 ; SE = .0048 ) chemotherapy regimens (p=0.0463)
(Table 4 & Figure 2). Moreover, the subset of women who received radiation had significantly
higher MNF (mean=.073; SE=.0033) than women who didn’t receive radiation (mean=.057;
SE=.0042) (Figure 6 & Table 11).

Race was also observed to be predictive of chromosomal instability frequencies (p=0.0037), with
values being significantly lower in the African American participants (mean=.059; SE= .0043)
compared to the Caucasian participants (mean=.071; SE= .0031). One might conjecture that this
association between acquired chromosomal instability and race is confounded by other influences
(e. g. age differences between the racial sub-groups). However, the consistent recognition of an
association between MN/cytome abnormality frequencies and race following the stepwise removal
of other potential confounding variables (including age and tumor characteristics) suggests that
there may be a separate, differential impact of race on chromosomal instability frequencies
following treatment for breast cancer (Table 11).

Tumor characteristics were also observed to be predictive of MN/cytome abnormality
frequencies with luminal B tumors being associated with lower overall chromosomal instability
values (mean=.057; SE=.0060), as compared to other types ( mean=.073; SE=.0024) (p=.0182).
Conversely, triple negative tumors were associated with higher values (mean=.0693; SE=.0043)
as compared to other tumors (mean=.0611; SE=.0031) (p= .0446) (Table 11). Given that the tumor
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characteristics determine the type of therapy regimen received by the study subjects, it is feasible
that this association is confounded by the impact of chemotherapy and/or radiation. However, as
noted previously in regard to race, the retention of consistent significant association values
between these tumor characteristic variables and MN/cytome abnormality frequencies following
the stepwise removal of the potentially related therapy variables suggest the presence of a separate
effect (above that related to therapies) for the tumor sub-types on peripheral blood MN/cytome
abnormality frequencies.

The best fit model also showed that the participants’ total perceived stress levels were predictive
of chromosomal instability frequencies (p=0.0123), with women reporting higher stress levels also
having higher values of instability. A second symptom associated with MN/cytome abnormality
frequencies was cognitive flexibility, with a significant positive relationship being observed
(higher instability values in women with higher cognitive flexibility domains)(p=.024). Although
complex attention measures were also initially suggestive of an association with MN/cytome
abnormality frequencies (Table 11), this variable did not yield a significant difference in the
reduced model.

No other PNS evaluated showed significant associations with acquired

lymphocyte chromosomal instability frequencies.
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Other variables that were tested and found to show no significant association with micronuclei
frequencies in the initial or final models were age, alcohol consumption, income, nutritional habits,
body mass index, menopausal state, tumor grade, tumor stage, luminal A and HER2+ tumor subgroups, types of surgery, depressive symptoms, anxiety, pain measures, fatigue measures,
memory, psychomotor speed, and overall cognitive function.
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Table 8. Demographic, health and lifestyle findings in study participants receiving
chemotherapy for breast cancer
African American
Caucasian
n=22 (100)
n=49 (100)
TAC
n=10
(45.451)

TC
n=6
(27.27)

TCH
n=6
(27.27)

TAC
n=29
(59.18)

TC
n=15
(30.61)

TCH
n=5
(10.20)

Total
n=71
(100)

5
(22.73)
3
(13.64)
1
(4.55)
1
(4.55)

4
(18.18)
2
(9.09)
0

3
(13.64)
3
(13.64)
0
0

1
(2.04)
1
(2.04)
7
(14.29)
6
(12.24)

0

0

6
(12.24)
6
(12.24)
6
(12.24)
11
(22.45)

3
(6.12)
2
(4.08)

19
(26.76)
15
(21.13)
17
(23.94)
20
(28.17)

44.00,
3.402

47.00,
2.52

50.50,
2.93

52.17,
1.73

57.13,
2.64

50.20,
6.35

7
(31.82)
3
(13.64)

3
(13.64)
3
(13.64)

2
(9.09)
4
(18.18)

11
(22.45)
18
(36.73)

5
(10.20)
10
(20.41)

3
(6.12)
2
(4.08)

BMI

31.99,
2.682

29.84,
2.54

35.56,
6.26

30.09,
1.47

26.77,
0.88

37.28,
4.70

Nutrition3

2.59,
0.182

2.22,
0.21

2.35,
0.25

2.72,
0.11

2.92,
0.13

2.67,
0.30

3
(13.64)
3
(13.64)

2
(9.09)
4
(18.18)

4
(8.16)
25
(51.02)

2
(4.08)
13
(26.53)

1
(2.04)
4
(8.16)

14
(19.72)
57
(80.28)

4
(8.16)
1
(2.04)

40
(56.34)
31
(43.66)

Demographic
Variable
Income
Less than
30,000
30,000-59,999
60,000-89,999
90,000+

Age

Menstrual Status
Pre- or PeriPost-

0

31
(43.66)
40
(56.34)

Current Smoking Status
Yes
No

2
(9.09)
8
(36.36)

Current Ethanol Consumption
Yes
3
1
2
19
11
(13.64)
(4.55)
(9.09)
(38.78)
(22.45)
No
7
5
4
10
4
(31.82)
(22.73)
(18.18)
(20.41)
(8.16)
1
Number in parenthesis is the percentage of study participants for the category (%)
2
Mean, standard error
3
Nutritional assessments for the participants’ intake of fruits and vegetables
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Table 9. Study participants’ breast tumor characteristics
African American
N=22 (100*)
TAC
TC
TCH
TAC
Tumor
(n=10)
(n=6)
(n=6)
(n=29)
Characteristic
(45.45*)
(27.27)
(27.27)
(59.18)
Luminal A
Yes

6
(27.27)
4
(18.18)

2
(9.09)
4
(18.18)

Yes

0

0

No

10
(45.45)

No

0

Caucasian
N=51 (100*)
TC
TCH
(n=15)
(n=5)
(30.61)
(10.20)

6
(27.27)

21
(42.86)
8
(16.33)

9
(18.37)
6
(12.24)

0

2
(4.08)
27
(55.10)

0

6
(27.27)

2
(9.09)
4
(18.18)

15
(30.61)

3
(13.64)
7
(31.82)

4
(18.18)
2
(9.09)

1
(4.55)
5
(22.73)

6
(12.24)
23
(46.94)

6
(12.24)
9
(18.37)

1
(4.55)
9
(40.91)

0

0

0

6
(27.27)

3
(13.64)
3
(13.64)

29
(59.18)

15
(30.61)

0

0

3
(13.64)
3
(13.64)

4
(18.18)
2
(9.09)

2
(4.08)
12
(24.49)
15
(30.61)

2
(4.08)
4
(8.16)
9
(18.37)

5
(10.20)

4
(18.18)
2
(9.01)
0

0

5
(10.20)
10
(20.41)
6
(12.24)
8
(16.33)

8
(16.33)
6
(12.24)
1
(2.04)
0

2
(4.08)
1
(2.04)
2
(4.08)
0

Total
(n=71)
(100)

5
(10.20)

38
(53.52)
33
(46.48)

3
(6.12)
2
(4.08)

7
(9.86)
64
(90.14)

0
5
(10.20)

20
(28.17)
51
(71.83)

2
(4.08)
3
(6.12)

6
(8.45)
65
(9.15)

0

5
(7.04)
28
(39.44)
38
(53.52)

Luminal B

Triple negative
Yes
No
HER2+,ER-,PRYes
No
Grade
1

1
(4.55)
5
(22.73)
4
(18.18)

2
3

0

Stage
I
IIA
IIB
IIIA

1
(4.55)
6
(27.27)
3
(13.64)
0

0

3
(13.64)
3
(13.64)
0

* Number (%) of participants.
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20
(28.17)
28
(39.44)
15
(21.13)
8
(11.27)

Table 10. Study participant treatments
African American
N=22 (100*)

Treatment
Surgery
Biopsy
Lumpectomy
Segmental
Simple

Caucasian
N=51 (100*)

TAC
(n=10)
(45.45*)

TC
(n=6)
(27.27)

TCH
(n=6)
(27.27)

TAC
(n=29)
(59.18)

TC
(n=15)
(30.61)

TCH
(n=5)
(10.20)

Total
(n=71)
(100)

3
(13.64)
4
(18.18)

0

0

0

0

0

1
(4.55)

2
(4.08)
8
(16.33)

6
(12.24)

1
(2.04)

5
(7.04)
20
(28.17)

1
(4.55)
2
(9.01)

5
(22.73)
1
(4.55)

3
(13.64)
2
(9.01)

1
(2.04)
18
(36.73)

6
(12.24)
3
(6.12)

0

3
(13.64)
7
(31.82)

0
6
(27.27)

1
(4.55)
5
(22.73)

2
(4.08)
27
(55.10)

1
(2.04)
14
(28.57)

5
(10.20)

7
(9.86)
64
(90.14)

9
(40.91)
1
(4.55)

5
(22.73)
1
(4.55)

5
(22.73)
1
(4.55)

23
(46.94)
6
(12.24)

12
(24.49)
3
(6.12)

1
(2.04)
4
(8.16)

55
(77.46)
16
(22.54)

4
(8.16)

16
(22.54)
30
(42.25)

Neoadjuvant
Yes
No

0

Radiation
Yes
No

* Number (%) of participants.
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Table 11. Mixed Effects Linear Model Fitting Assessment of Predictive Associations
of Variables with Micronuclei/Cytome Abnormality Frequencies.
Base Model1
Final model2
Least Squares Std.
Variable
p value
Mean
Error p value
Visit
<0.0001
1
0.050
0.0044
2
0.067
0.0042
3
0.075
0.0043
4
0.069
0.0045
Age
0.973
Race
0.0037
African American
0.059
0.0043
Caucasian
0.071
0.0031
Chemotherapy
0.0463
TAC
0.063
0.0043
TC
0.058
0.0048
TCH
0.071
0.0042
Radiation
0.0004
Yes
0.073
0.0033
No
0.057
0.0042
Radiation by visit
0.0077
BMI
0.437
Income
0.373
Menopausal status
0.507
Alcohol consumption
0.078
Tumor grade
0.805
Tumor stage
0.234
Luminal A tumors
0.926
Luminal B tumors
0.0182
Yes
0.057
0.0060
No
0.073
0.0024
Triple negative tumors
0.0446
Yes
0.0693
0.0043
No
0.0611
0.0031
HER2 +
0.640
Surgery
0.262
HADS depressive symptoms
0.814
HADS anxiety
0.104
BPI Measures
Worst pain
0.329
Least pain
0.293
Average pain
0.166
Current pain
0.416
Pain relief
0.598
Pain interference
0.236
BFI Measures
Total fatigue
0.188
Current fatigue
0.664
Usual fatigue
0.100
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Worst fatigue
Fatigue interference

0.171
0.1571

Perceived Stress
Nutrition (fruits and vegs)
0.323
Cognitive Measures
NCI
0.495
Memory
0.991
Complex attention
0.013
Psychomotor speed
0.318
Cognitive Flexibility
1
The base model, which was determined by the study design, was:

0.0123

0.0238

MN frequency=Visit + Chemotherapy (3 types) + Radiation therapy + Visit by Chemotherapy* +
Visit by Radiation therapy* with the study subject being a random effect
*The visit by chemo and visit by radiation interaction variables allowed these values to differ across time points.
2

The final model reflects the variables that remained significantly associated with MN frequencies after
stepwise removals.
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0.10

0.09

MN proportion

0.08

0.07

0.06

0.05
Anthracyclin/Cyclophosphamide +Taxol
Taxol/Cyclophosphamide
TC with Herceptin

0.04

0.03
1

2

3

4

Visit

Figure 5: The effect of different types of chemotherapy on MN proportions.
Women treated with TCH (mean=0.071) showed the overall highest MNF followed by TAC
(mean=0.063) then TC (mean=0.058) (p=0.04). However, at visit 2 (during the administration of
chemotherapy), patients treated with TAC had the highest level of acquired changes in MNF
followed by TC, then TCH.
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0.10
No radiation therapy
Recieved radiation therapy

0.09

MN Proportion

0.08

0.07

0.06

0.05

0.04

0.03
1

2

3

4

Visit

Figure 6: The effect of radiotherapy on MN proportions.
MNF in women treated with radiation were not significantly different from those of women who
were not treated with radiation at visit 1 or 2 (before the administration of radiation). However, at
visit 3, the subset of women treated with radiotherapy had significantly higher MNF. (Radiation
by visit, p=0.0077). Women treated with radiation had overall higher frequencies (mean=0.073)
than women who were not treated (mean=0.057) (p= 0.0004)
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Discussion

In this longitudinal study we showed that MN/cytome abnormality frequencies in lymphocytes
increase after treatment for breast cancer and remain at an increased level for at least a year
following the initiation of treatment. In addition to the timing of the receipt of therapy, other
factors significantly associated with acquired MN/cytome instability frequencies were therapy
regimens (types of chemotherapy and/or radiation), race, tumor characteristics (luminal B or triple
negative tumors), and a subset of PNS (total perceived stress and cognitive flexibility domains).

The largest influences on lymphocyte MN/cytome abnormality frequencies were the
chemotherapy and radiation treatments given to the participants and the time points of assessment
relative to the administration of these treatments. Since both of these types of treatment are
genotoxic and can induce DNA damage, it is not surprising that they were associated with
significant increases in MN/cytome abnormality frequencies. At visit 2, during the administration
of chemotherapy, women treated with TAC acquired the greatest increase in chromosomal
instability levels. The fact that the instability levels were higher in the TAC compared to TC
treatment cohorts points to adriamycin as the primary factor contributing to this comparative
increase. Adriamycin is a member of the anthracyclin class of compounds. Although this drug is
widely used, the mechanism(s) for its effectiveness in preventing/reducing cancer cell proliferation
is/are not fully known, with some investigators proposing that it induces cell apoptosis or
senescence by inhibiting topoisomerase II, while others cite roles for DNA adduct formation,
oxidative stress, ceramide overproduction and/or torsion-induced nucleosome destabilization as
the causal means for this drug’s efficacy (Gewirtz 1999; Senchenkov , et al., 2001; Minotti, et al.,
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2004; Yang, et al., 2014). While the mechanism(s) of action for adriamycin (also known as
doxyrubicin) remain(s) controversial, this drug has consistently been shown to induce
chromosomal instability (Table 7), with telomere dysfunction also consistently being associated
with this increase in acquired chromosomal abnormality frequencies (Elmore, et al., 2002; Khan,
et al., 2009; Li, et al., 2012). Thus, the results of our study are in agreement with the in vitro
findings of several other investigators and the in vivo results of the few other groups reporting
frequencies following treatment in humans.

While the cohort of participants receiving TAC treatment had the highest levels of
chromosomal instability at time point 2, the cohort receiving TCH showed the highest overall
change in MN proportion levels Table 4.

Explanations for this difference in MN/cytome

abnormality frequencies between treatments based on the time of specimen collection may reflect
the length of the chemotherapy regimen (e.g. the number of cycles for the treatment), the
mechanism(s) of the drugs used (docetaxel causes microtubule depolymerization leading to
apoptosis, the administration of Herceptin (a targeted monoclonal antibody that binds to the HER2
receptor), and/or the follow-up radiation treatments administered. Radiation therapy was also
identified to have a significant predictive influence on the women’s acquired lymphocyte
chromosomal instability frequencies. As with Adriamycin, radiation exposure has been
consistently associated with increased levels of chromosomal instability in human cells, primarily
through in vitro study designs (Table 7).

An unexpected finding in this study was the significant predictive association of race on
MN/cytome abnormality frequencies, with the Caucasian study participants having higher overall

59

instability frequencies than the African American participants. To our knowledge, associations
between lymphocyte MN/cytome abnormality frequencies and race in women treated for breast
cancer have not been previously reported. Also, there is a paucity of information available
regarding MN frequencies in healthy subjects from different racial groups (Huen, et al., 2006).
However, the results of population cytogenetics studies are controversial, with some investigators
suggesting a difference in constitutional chromosomal abnormality frequencies between people
from different racial backgrounds, while most have seen no clear or consistent differences
(Sherman, et al, 2007; Hook, et al., 1999; Hook and Porter, 1977). It is interesting to note that
African American women have been described to have significantly lower levels of dietary-related
oxidative DNA damage than white women, suggesting that there may be race-related differences
in the cellular processes involved in oxidative DNA damage recognition/repair (Watters et al
2007). While our step-wise statistical approach suggests this observation is an independent
association, given the inter-relatedness of human epidemiology variables, one cannot fully rule out
the possibility that it may be confounded by other factors, such as age or tumor characteristics. For
example, the Caucasian women participating in this study were significantly older than the African
American participants. This difference is consistent with data from the American Cancer Society,
which shows that African American women develop more aggressive forms of breast cancer at
younger ages and show a poorer prognosis than Caucasians. However, given that increasing age
has consistently been shown to be positively correlated with MN frequencies in healthy women
(reviewed by Fenech, et al., 2011; Volders-Kirsch, et al., 2011), it is possible that the age of the
Causasian participants contributed to their observed increased rate of MN/cytome abnormalites.
We also observed differences in annualized income levels and alcohol consumption rates between
the racial groups in our study, with the Caucasian women having significantly higher incomes and
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alcohol consumption practices than the African American women. Therefore, given the interrelated nature of the data, the basis for the association between race and MN/cytome abnormality
frequencies in this study is not clear.

One aspect of breast cancer that has been associated with racial differences is the proportion of
breast cancer tumor sub-groups in African American compared to Caucasian populations (Carey,
et al. 2006). While not significantly different, a trend toward a higher proportion of HER2 positive
(18.2%) and triple negative (36.4%) tumors was noted in the African American participants in our
study compared to those noted in the Caucasian participants. This trend is consistent with the
pattern reported by Carey, et al (2006) in their study of women from North Carolina. The
proportions of tumor sub-types among the African American and Caucasian women participating
in this investigation were not significantly different from those reported by Carey, et al. (2006)
(Table 7). Thus, the breast tumors in our participants appear to be representative of those seen in
larger populations. The treatment regimen for each study participant is determined, in large part,
by her breast tumor characteristics. Therefore, if treatments are related to chromosomal instability
levels, one might also anticipate detecting the presence of a relationship between tumor
characteristics and acquired chromosomal changes. Indeed, our stepwise reduction model showed
a predictive influence of tumor characteristics on MN/cytome abnormality frequencies for the
subset of women having luminal B or triple negative tumors that appears to be a separate influence
(beyond that of treatment). The interesting observation of a potential influence of tumors on
acquired chromosomal instability levels in peripheral blood is in agreement with the previous
reports by other investigators who have consistently detected higher pre-treatment MN frequencies
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in women (and men) having a variety of different types of cancer when compared to age-matched
controls without cancer (reviewed by Fenech, et al., and Kirsch-Volders, et al. 2011).

The basis for the influence of tissue-specific tumors on acquired chromosomal instability levels
in peripheral blood (and possibly other somatic tissues) is not clearly known. However, one factor
that could contribute to this increase in our population is stress, since the baseline values were
collected after the participants had received their diagnosis of cancer (but before treatment). To
our knowledge, this is the first study to identify a significant predictive association between stress
and acquired lymphocyte chromosomal instability in women with breast cancer, with elevated
stress levels being associated with higher frequencies of MN/cytome abnormalities. In the only
other previous study in which a significant association was observed between stress and an
increased rate of peripheral blood chromosomal instability, twins exposure to childhood sexual
abuse were found to have significantly higher frequencies of MN than their unexposed identical
co-twins (York et al. 2013). Furthermore, the data from the discordant identical twin study
suggested that chromosomal instability accumulated throughout the lifespan of the twins exposed
to childhood sexual abuse, leading the authors to speculate that the increased incidence of health
problems observed in people experiencing early life trauma might be associated with acquired
somatic chromosomal abnormalities (York, et al., 2013). While there is a paucity of studies
investigating associations between stress and acquired chromosomal instability frequencies in
women with breast cancer (or any type of cancer), several investigators have reported an
association between stress and telomere shortening (Shalev et al 2013, Surtees et al. 2011);
especially chronic stress (Quinlan et al 2014). Given that telomere shortening has also consistently
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been observed to result in increased frequencies of acquired chromosomal abnormalities, it follows
that stress would also be associated with chromosomal instability.

A second PNS identified to have a significant predictive association with MN/cytome
abnormality frequencies was cognitive flexibility domain measures. Given that cognitive
flexibility domains have been one of the aspects of cognition impacted by chemotherapy (along
with working memory, processing speed, multitasking, and attention)(Wefel et al 2012; Kesler et
al 2013) this association was of particular interest. However, the relationship observed between
chromosomal instability and cognitive flexibility domain measures was positive, with women
having higher cognitive flexibility values also having higher chromosomal instability frequencies.
Our initial hypothesis was that increased levels of soma-wide chromosomal instability could lead
to the presence of a clone(s) with a chromosomal imbalance and that this imbalance would lead to
compromises in cognitive function. Therefore, the observation of higher cognitive flexibility
domains being predictive of higher MN/cytome abnormality frequencies seemed contradictory of
our initial conjecture. This impression is based on the concept that higher MN/cytome abnormality
frequencies are considered to be a negative outcome indicating the presence of chromosomal
instability. However, an alternative interpretation is that these cytological structures serve as
indicators that the cell has successfully recognized the presence of chromosomal instability and
has eliminated the abnormality from the cell, thereby reducing/preventing the accumulation of
DNA/chromosomal damage. Thus, it is feasible that women having higher MN/cytome
abnormality frequencies in response to genotoxic agent exposures may actually have more
efficient repair systems than women with lower MN/cytome abnormality values. Interestingly, the
results from in vitro time-lapse studies have shown that the frequency of apoptosis is higher in
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cells having a MN than cells without a micronucleus, suggesting that these cytome measures are
related to cellular fate (Utani et al 2010). While intriguing, this association between lymphocyte
instability and cognitive flexibility warrants further study before clear conclusions can be derived.

In addition to the significant associations we observed, we also showed a lack of predictive
associations for several factors. Of note, no significant association was observed between age and
MN/cytome abnormality frequencies in this study. Other investigators have also failed to detect
an age effect for MN frequencies in patients with cancer, or specifically with breast cancer, despite
the clear association between age and MN frequencies that has consistently been observed in
healthy adults (Table 7)(Fenech, et al., 2011; Kirsch-Volders, et al., 2011). This lack of a clear,
independent influence of chronological age on lymphocyte MN frequencies in women with breast
cancer could reflect the narrow age range of the participants sampled in this (and other studies) of
women with breast cancer. Alternatively, the influence(s) of factors related to breast cancer
development may over ride or “mask” the effects of age. For example, the large effects of the
treatments may mask any impact attributable to age.

In summary, we determined that lymphocyte chromosomal instability frequencies increase in
women following their treatment for breast cancer, with these increased frequencies persisting for
at least one year following treatment. We identified 8 factors (time from treatment, the type of
chemotherapy, radiotherapy, race, luminal B tumor sub-group, triple negative tumor sub-group,
stress, and cognitive flexibility domains) that were predictive of these MN/cytome abnormality
frequencies. Of particular interest was the recognition of stress as a contributor to increased levels
of chromosomal instability since this factor has the potential to be modulated through intervention.
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The recognition of biomarkers associated with the development/persistence of PNS, such as
MN/cytome abnormality frequencies, could lead to a better understanding of the biological basis
for the adverse side-effects associated with cancer treatment and could also provide a basis for the
future development of an algorithm to identify individuals most “at risk” for acquiring PNS.
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Chapter 3

Acquired Epigenetic Changes in Women Treated for Breast Cancer:
Methylation patterns in the peripheral blood.

Introduction
Breast cancer (BC), which affects approximately 1 in 8 females in the US, is the most
common invasive cancer in women (American Cancer Society, 2013). BC accounts for about 29%
of women’s cancer and is the second most common cause leading to mortality in females
(American Cancer Society. 2013, Siegel et al. 2014). Due to advances in early detection and
management of BC, the survival rates for women with BC have steadily increased during the last
two decades, culminating in an estimation of about 2.5 million BC survivors. However, a major
subset of BC survivors develop short and long term side effects as result of their treatments, or the
cancer itself. These side effects include anxiety (Badger et al 2007), depression (Badger et al 2007),
fatigue (Berger et al. 2010), sleep disturbances (Lee et al 2004), pain (Utne et al 2010, Valeberg
et al 2008), and cognitive dysfunction (Wefel et al 2011) and can be collectively referred to as
psychoneurological symptoms (PNS). While there is an essential need to retain and continue to
enhance survivorship following treatment for BC, there is also a critical need to reduce the adverse
side effects associated with BC and its treatment to allow for improvements in the quality of life
for the survivors.

BC is a heterogeneous condition, making pathological diagnostic classifications, and, in turn,
treatments decisions, challenging.

Moreover, significant variability in drug response and
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outcomes has been observed in individuals treated with identical therapy regimens (Polyak et al
2011, Westbrook & Stearns 2013). Gene expression analyses of tumor cells have resulted in
improvements in recognizing optimal therapeutic approaches to be followed to prevent cancer cell
proliferation and metastasis, but there is a paucity of information available about “personalized
medicine” approaches to identify the prevalence or causes of the soma-wide adverse side effects
that arise following treatments for BC (or the cancer itself) (Perou et al 2000, Sorlie et al 2001,
Sorlie et al 2003; The Cancer Genome Atlas 2012, Byler et al. 2014). An optimal approach for
treating each person diagnosed with BC would not be determined solely by the classification of
their tumor’s characteristics, but would also include recognition of the individual’s
genetic/exposure-related susceptibility to cellular responses from the therapeutic agents
(chemotherapy and radiation) being administered, as well as the potentially long term systemic
cellular biological changes that might result from the tumor and its treatment, such as potential
acquired epigenetic alterations.

Epigenetics is a relatively new, but very promising and rapidly growing area of research that
has been suggested to be the epicenter of modern medicine since it provides explanations for the
relationships between environment, genetic background and disease (Feinberg 2007, 2008). DNA
methylation is one of the most stable and well-characterized epigenetic mechanisms (Jirtle and
Skinner 2007). DNA methylation patterns in different tissues, including blood, are known to be
sensitive to environmental insults, including (but not limited to) those associated with the aging
process (Rakyan et al 2010, Teschendorff et al 2010) alcohol intake (Choi et al 2009, Christensen
et al 2010) and smoking (Breitling et al 2011). It also plays an important role in inflammation
(Wierda et al 2010), in developing cancers (Heyn and Esteller 2012) and in behavior/psychiatric
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disorders (Mehler et al 2008, Narayan and Dragunow 2010). Typically, in normal cells, promoter
CpG islands are hypomethylated, while repetitive DNA sequences in the genome are
hypermethylated. Studies of genome-wide DNA methylation in cells from a wide range of
different types of cancer have revealed that this typical scenario tends to be abnormally reversed
(Feinberg et al 2006).

Investigations of DNA methylation patterns focused on BC tumors have been completed by
several investigators, with their study results allowing for improvements in tumor classification,
prognosis, and management (Szyf 2012, The Cancer Genome Atlas 2012, Byler et al. 2014, Van
De Voorde et al 2012, Huang et al 2011). DNA methylation patterns thought to be specific to the
tumor have also been found in cell-free DNA (which is released from dead cancer cells) that is
present in serum/plasma (Sidransky 2002, Van De Voorde et al 2012), with some investigators
studying the association between targeted methylation patterns and prognosis, while others have
monitored changes in targeted methylation patterns that arise in response to a treatment. However,
the utility of assessing cell free DNA in serum/plasma is limited due to: (1) the inability to
adequately/accurately follow-up a patient’s response to a treatment after the surgical removal of
the tissue; and (2) the amount of presumed tumor-derived cell-free DNA in serum/plasma is very
small and tends to lack sufficient quality (due to degradation) for use in the sensitive genetic
techniques needed for genome-wide or targeted genetic/epigenetic evaluations. Thus, there is a
need for an assay that can be used to evaluate potential associations between cellular responses
that are acquired and persist following treatment for BC, with a goal of applying this technology
to identify or stratify women who are most “at risk” for developing PNS or other adverse side
effects following their treatment for BC.
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Given that the effects of chemotherapy and radiation have been shown to have a soma-wide
impact, one approach for monitoring genetic and/or epigenetic changes that arise in response to
therapy would be to study the patterns of cells in peripheral tissues. Furthermore, based on the
conjecture that inflammation plays a key initiating role in the cascade of biological changes
resulting from chemotherapy (as well as its ease of access for evaluation), peripheral blood seems
to be a strong specimen for evaluating biological changes related to the acquisition of adverse side
effects related to BC treatment. Few investigators have examined the association between BC - or
cancer in general- and DNA methylation patterns in peripheral blood. However, the limited
number of investigations published have indicated that peripheral blood is effective for identifying
biomarkers indicative of an increased risk for developing breast cancer, and/or the presence of
cancer (Wu et al 2011, Choi et al 2009, Cho et al 2010 , Wong et al 2010, Iwamoto et al 2011,
Widschwendter et al 2008).

An

important

first

step

in

understanding

factors

contributing

to

the

acquisition/persistence of PNS in a subset of BC survivors is to identify biological changes that
arise in women’s cells following their treatment for breast cancer and to determine if these changes
vary with tumor characteristics and/or treatment regimens. We hypothesize that chemotherapy for
BC leads to the acquisition of soma-wide epigenetic alterations and that these alterations can be
detected in peripheral blood cells and will vary based on the type of chemotherapy administered.
To test this hypothesis, we designed a longitudinal study to investigate acquired changes in
methylation patterns in PBCs that were obtained from women diagnosed with BC; (1) before
treatment (baseline) and (2) during the administration of different types of chemotherapy.
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Materials and Methods

Study Participant Ascertainment and Specimen Collection:
A total of 68 women with early stage (I to IIIA) breast cancer, who ranged in age from 23 to
71, were ascertained through 5 regional cancer centers in Central Virginia, including the Massy
Cancer Center (MCC) at Virginia Commonwealth University. To identify potential study
participants, a member of the research team attended the weekly interdisciplinary Breast Health
meetings at Virginia Commonwealth University Health System (VCUHS). Study eligibility
criteria for participants were: (1) gender (only females were included since too few male
participants were available for study); (2) an age of 21 years or older; and (3) a diagnosis of early
stage breast cancer with a scheduled visit to receive chemotherapy. Exclusion criteria were: (1) a
history of previous cancer, or chemotherapy; (2) a diagnosis of dementia; (3) active psychosis; or
(4) a history of immune-related diagnoses (e.g. multiple sclerosis and systemic lupus
erythematosus). After providing their informed consent (VCU IRB #HM 13194), participants were
enrolled and their first study visit was scheduled prior to the initiation of chemotherapy. Study
visits took approximately one hour to complete. A peripheral blood sample was collected from
each participant prior to the receipt of treatment (baseline or visit 1) and at the midpoint of the
chemotherapy treatments (visit 2). The blood specimens were collected by venipuncture or through
an existing access device. The specimens were coded prior to their delivery (same day) to the
cytogenetics lab to ensure that the geneticists completing this study were unaware of the clinical
or treatment history of each participant at the time of sample processing and/or evaluation.
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Chemotherapy Treatment Information

Medical records were used to determine chemotherapy treatments administered. The three
primary types of chemotherapy regimens included: (1) Taxotere (docetaxel), Adriamycin
(doxorubicin), and cyclophsophamide [TAC]; (2) Taxotere and Cyclophosphamide [TC]; or (3)
Taxotere (docetaxel), Carboplatin (paraplatin); and Herceptin (transtuzumab) [TCH].

DNA preparation and methylation assessment:
Genomic DNA was isolated from whole blood according to standard methods using the
Puregene DNA Isolation Kit (Qiagen). An aliquot (500 ng per study participant) of DNA was then
sent to Hudson Alpha Institute for Biotechnology for bisulfite conversion, using standard methods
(Zymo Research EZ Methylation Kit) and genome-wide methylation pattern assessment, using the
450K HumanMethylation Chip, according to the manufacturer’s protocol (Illumina). The 450K
HumanMethylation Chip interrogates 485,764 genome-wide targets. Both specimens (baseline and
mid-chemo visits) from each study subject were localized to the same array to avoid any potential
artifactual differences in methylation patterns that might arise due to “batch” effects. Also, to
evaluate reproducibility of the assay and allow for the correction of any potential batch effects that
might be present, replicate evaluations of a single specimen were completed (the same specimen
was evaluated in every batch). Intensity data from the scanned arrays were imported into Illumina’s
GenomeStudio software and the minfi Bioconductor (Aryee et al 2014, Gentleman et al 2004) in
the R programming environment (R core team 2014) to obtain  values for each probe.
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Genome-Wide Methylation Data Analyses
Recognizing that high-throughput assays are subject to unwanted technical variation and that
chemotherapy could elicit global DNA methylation changes, the functional normalization
procedure was applied to the raw intensity values (Fortin et al 2014). Functional normalization
builds upon quantile normalization by estimating the first 2 (default) principal components from
inbuilt control probes as covariates to adjust for technical variation and is applied to the methylated
and unmethylated intensities separately along with separate fits to the type I and type II probes; it
has been shown to perform well even in the presence of batch effects. The primary motivation for
this approach was to avoid placing unrealistic constraints across sample groups were likely to have
very different marginal distributions (ie., pre- verus post-chemotherapy). In addition, since the
performance of probes containing single nucleotide polymorphisms (SNPs) can be variable
(Bibikova, et al., 2011), probes containing SNPs that overlapped the CpG site or at that were
localized to the single base extension were excluded. Because the intensity value, , reported for
each CpG site represents “proportion methylated”, which is constrained to an interval value of 0
to 1, where a  of 1 indicates complete methylation and 0 indicates no methylation, the normalized
intensity values were transformed using the M-value procedure to promote normality (Du, et al.,
2010). The M-value is calculated as a logit transformation of the methylated and unmethylated
intensity ratio along with an added term to offset potentially small values.

Statistical analyses were then performed on the normalized M-values from the baseline
compared to mid-chemotherapy samples. For each CpG site, differential methylation between
baseline and treatment specimens was tested using a mixed effect linear model in the R
programming environment (R Development Core Team, 2011), including a random effect term to

72

account for the paired status of observations. An additional term was included to account for the
relative proportion of neutrophil levels (ie., the largest and most variable blood cell proportion) to
account for changes in blood cell types that could differ between sample time points. This term
controlled for a potential bias in results stemming from DNA methylation changes reflective of
differences in white blood cell proportions following chemotherapy, but not the chemotherapy
itself. To adjust for the multiple hypothesis tests, the p-values were used to estimate the false
discovery rate (FDR) following Benjamini and Hochberg’s (1995) method. (Normalization of the
data, calculation of the M-Values and detection of the differentially methylated sites were
performed by Dr. York).

The R program was then used to create pie charts and the DAVID gene functional
classification tool (Huang, et al., 2007) was used to identify biological relationships among the
differentially methylated sites.
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Results

A total of 68 women were initially included in the study and methylation patterns were analyzed
in each woman before (Baseline=T1) and during chemotherapy (Mid-chemo =T2). A single paired
sample showed lower median intensity values for both the unmethylated and methylated set of
probes as compared to the other samples. Therefore, this participant’s specimens were excluded,
resulting in a total of 67 paired samples that were analyzed. All women were diagnosed at early
stage BC (I-IIIA). The women evaluated included 19 African Americans, and 48 Caucasians. The
women were treated with either TAC (n=35), TC (n=22), or TCH (n=11). Using the normalization
and SNP exclusion processes described in the methods section, a total of 18,131 probes were
excluded from the analysis, resulting in a total of 467,633 probes that were evaluated for the paired
specimens from each participant.

Acquired alterations in methylation patterns were observed in response to chemotherapy
(Figure 7). When methylation patterns were compared between visit one (baseline) and visit 2
(mid-chemo), 1265 significant differentially methylated sites (DMSs) were detected (FDR<.01,
<10% mean within pair difference) (Table 12). Acquired reduction in methylation (e.g. relative
hypomethylaion) was seen more frequently than increases in methylation (relative
hypermethylation) (Table 12 and Figure 8). A total of 788 of the 1265 significant differentially
methylated CpG sites (62.3 %) showed relative hypomethylation following chemotherapy; while
477 of 1265 CpG sites (37.7%) showed relative hypermethylation. Observed changes involved
multiple types of sequences, but were most prevalent in the “open sea” regions of the genome for
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both hypo & hyper methylated sites (Table 12 and Figure 8). Of particular interest is the
methylation status of the CpG island probes, since these sites are most clearly associated with gene
function. Patterns differences showing increased methylation levels at the mid-chemo timepoint
were observed in 8.0% of the CpG islands, with changes resulting in lower methylation values
being seen in only 1.3% of the CpG islands. The significant DMSs showed altered patterns for
genes involved in several biological processes or pathways including (but were not limited to)
those involved in transcription regulation, signal transduction pathways, immune response,
hemostasis, neuronal regeneration, cell cycle and cell death (Tables 13-15). In particular, 51% of
the DMSs were associated with phosphorylation processes (p=3.4x10-16). A subset of the
significantly differentially methylated sites within interesting genes is listed in Table 16, along
with a description of the genes’ biological functions.
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Table 12: Distribution of acquired methylation changes in relation to genomic sites.

Sites
Total Significant; 1265
Hypo; 788 (62.3 %)
Hyper; 477 (37.7%)

Island*
N (%)
48 (3.8)
10 (1.3)
38 (8.0)

N-Shelf*
N (%)
82 (6.5)
55 (7.0)
27 (5.7)

N-Shore*
N (%)
106 (8.4)
61 (7.7)
45 (9.4)

Open Sea*
N (%)
851 (67.3)
545 (69.2)
306 (64.2)

S-Shelf*
N (%)
98 (7.7)
69 (8.8)
29 (6.1)

S-shore*
N (%)
80 (6.3)
48 (6.1)
32 (6.7)

* CpG Island is defined as a DNA region > 500bp, GC >= 55% and observed/expected CpG ratio >.65 (Takai and
Jones 2002).
* Shore is 2 kb from CpG island. The N and S indicate upstream and downstream of the CpG island, respectively.
* Shelf is 4-6 kb from CpG island. The N and S indicate upstream and downstream of the CpG island, respectively.
* Open sea > 6kb from CpG island
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A total of 1265 significantly DMRs were detected at (FDR= 0.01 and >10% mean within pair
difference) (a) sites with relative hypomethylation (62%) were acquired more frequently than
hypermethylation (37.7%). (b) Acquired alterations in DNA methylation were distributed across
different genomic sequences with the majority occurring in the open sea sequences (67.3%),
followed by N-shore (8.4%), S-Shelf (7.7%), N-shelf (6.5%), S-shore (6.3%), and Islands
(3.8%). (C) & (D) Distribution of acquired relative hypo & hyper methylation across the
different sequences. Both were mainly involved in the open sea sequences (69.2% & 64.2%)
respectively. More acquired hypermethylation alterations were acquired at CpG islands (8%)
when compared to acquired hypomethylation (1.3%).
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Table 13. Subset of Functional Roles Associated with the Significantly DMSs (based
on Keywords)*
Genes with DMSs
#
%

Term
Phosphoprotein
Cytoplasm
Activation of Protein Kinase Activity
Positive Regulation of Transferase Activity
Alternative Splicing
Negative Regulation of Gene Expression
Positive Regulation of Kinase Activity
Splice Variant
Regulation of Phosphate Metabolic Process
Regulation of Phosphorus Metabolic Process
Positive Regulation of Protein Kinase Activity
Sequence Variant
Polymorphism
Regulation of Phosphorylation
Mutagenesis Site
Intracellular Signaling Cascade
Regulation of Transferase Activity
Regulation of Protein Amino Acid Phosphorylation
Regulation of Kinase Activity
Negative Regulation of Transcription
Repressor
ATP-Binding
Regulation of Protein Kinase Activity
Coiled Coil
Transcription Activator Activity
Chromosomal Rearrangement
Zinc Finger, C3HC4 RING-Type
Transferase
Negative Regulation of Transcription from RNA Polymerase II
Promotor
Calcium Transport
Type II Diabetes Mellitus
Phosphorus Metabolic Process
Negative Regulation of Transcription, DNA-Dependent
Nucleotide-Binding
Pleckstrin Homology-Type
Nucleoplasm
Phosphatidylinositol Signaling System
Binding Site: ATP
Limb Morphogenesis
Appendage Morphogenesis
Nucleotide Binding
Kinase
Phosphorylation
Calcium Channel
Phosphotransferase
Negative Regulation of RNA Metabolic Process
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325
154
16
24
287
38
23
285
36
36
22
425
409
34
96
69
29
18
28
33
30
67
27
93
30
22
20
68
22

51.1
24.2
2.5
3.8
45.1
6.0
3.6
44.8
5.7
5.7
3.5
66.8
64.3
5.3
15.1
10.8
4.6
2.8
4.4
5.2
4.7
10.5
4.2
14.6
4.7
3.5
3.1
10.7
3.5

P-Value
3.9E-16
2.5E-7
6.9E-6
7.3E-6
8.4E-6
8.6E-6
1.3E-5
1.9E-5
2.2E-5
2.2E-5
2.4E-5
2.7E-5
4.1E-5
5.4R-5
6.2E-5
6.8E-5
7.0E-5
8.3E-5
8.7E-5
9.4E-5
1.2E-4
1.2E-4
1.2E-4
1.4E-4
1.8E-4
2.0E-4
2.1E-4
2.9E-4
3.0E-4

Benjamini
1.5E-13
5.5E-5
1.7E-2
9.2E-3
1.3E-3
7.2E-3
8.0E-3
3.3E-2
1.1E-2
1.1E-2
9.9E-3
2.3E-2
4.6E-3
1.9E-2
3.6E-2
2.1E-2
2.0E-2
2.1E-2
2.0E-2
2.0E-2
1.0E-2
8.9E-3
2.4E-2
8.8E-3
1.3E-1
1.1E-2
2.0E-1
1.4E-2
5.2E-2

11
9
54
36
78
23
49
11
33
12
12
105
39
46
9
17
26

1.7
1.4
8.5
4.1
12.3
3.6
7.7
1.7
5.2
1.9
1.9
16.5
6.1
7.2
1.4
2.7
4.1

3.2E-4
3.8E-4
4.0E-4
4.8E-4
4.8E-4
4.9E-4
4.9E-4
5.0E-4
5.1E-4
5.2E-4
5.2E-4
5.4E-4
5.5E-4
5.7E-4
6.0E-4
6.1E-4
6.2E-4

1.4E-2
5.3E-2
6.5E-2
7.3E-2
1.9E-2
2.3E-1
1.8E-1
3.6E-2
2.0E-1
7.4E-2
7.4E-2
1.8E-1
2.0E-2
7.7E-2
2.0E-2
1.9E-2
7.9E-2

Positive Regulation of JUN Kinase Activity
7
1.1
Protein Amino Acid Phosporylation
40
6.3
Negative Regulation of Nucleobase, Nucleoside, Nucleotide and
33
5.2
Nucleic Acid Metabolic Process
Embryonic Limb Morphogenesis
11
1.7
Embryonic Appendage Morphogenesis
11
1.7
Appendage Development
12
1.9
Limb Development
12
1.9
Positive Regulation of Macromolecule Metabolic Process
48
7.5
Adenyl Nucleotide Binding
78
12.3
Negative Regulation of Nitrogen Compound Metabolic Process
33
5.2
Zinc-Finger
78
12.3
Pleckstrin Homology
21
3.3
Nucleoside Binding
79
12.4
Regulation of Transcription from RNA Polymerase II Promotor
42
6.6
Apoptosis
25
3.9
*Subset selected to include only those associations having a P-value of E-4 or smaller
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6.3E-4
6.3E-4
6.6E-4

7.7E-2
7.3E-2
7.3E-2

7.1E-4
7.1E-4
7.3E-4
7.3E-4
7.5E-4
7.7E-4
8.3E-4
8.3E-4
9.3E-4
9.3E-4
9.6E-4
9.7E-4

7.5E-2
7.5E-2
7.4E-2
7.4E-2
7.3E-2
1.7E-1
7.7E-2
2.4E-2
2.8E-1
1.6E-1
8.6E-2
2.7E-2

Table 14. Biological Pathways Associated with the significantly DMSs (Panther
pathways search).
Term
PDGF Signaling Pathway
Endothelin Signaling Pathway
Inflammation Mediated by Chemokine and Cytokine Signaling
Pathway
T Cell Activation
Angiotensin II-Stimulated Signaling Through G Proteins and
Beta-Arrestin
VEGF Signaling Pathway
B Cell Activation
Integrin Signaling Pathway
Vitamin D Metabolism and Pathway
Purine Metabolism
Ras Pathway
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Genes with DMSs
#
%
20
13
25

0.3
0.2
0.4

P-Value
6.5E-4
1.3E-3
7.0E-3

Benjamini
5.7E-2
5.7E-2
1.9E-1

13
8

0.2
0.1

9.9E-3
1.0E-2

2.0E-1
1.7E-1

10
10
18
4
3
9

0.2
0.2
0.3
0.1
0.0
0.1

1.0E-2
1.7E-2
2.6E-2
4.3E-2
5.1E-2
6.0E-2

1.4E-1
2.0E-1
2.6E-1
3.6E-1
3.8E-1
4.0E-1

Table 15. Biological Pathways Associated with the significantly DMSs (KEGG
pathways search).
Genes with DMSs
#
%

Term
Type II Diabetes Mellitus
Phosphatidylinositol Signaling System
Gap Junction
Natural Killer Cell Mediated Cytotoxicity
Regulation of Actin Cytoskeleton
Chemokine Signaling Pathway
GnRH Signaling Pathway
mTOR Signaling Pathway
MAPK Signaling Pathway
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Focal Adhesion
T Cell Receptor Signaling Pathway
VEGF Signaling Pathway
Oocyte Meiosis
Vascular Smooth Muscle Contraction
Fructose and Mannose Metabolism
Prion Diseases
Long-Term Potentiation
Neurotrophin Signaling Pathway
Apoptosis
Chondroitin Sulfate Biosynthesis
Nicotinate and Nicotinamide Metabolism
Dilated Cardiomyopathy
Chronic Myeloid Leukemia
Aldosterone-Regulated Sodium Reabsorption
Type I Diabetes Mellitus
Calcium Signaling Pathway
Fc Epsilon RI Signaling Pathway
Pathways in Cancer
Toll-Like Receptor Signaling Pathway

9
11
11
13
17
15
10
7
19
9
7
8
15
10
8
10
10
5
5
7
10
8
4
4
8
7
5
5
12
7
19
8
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0.1
0.2
0.2
0.2
0.3
0.2
0.2
0.1
0.3
0.1
0.1
0.1
0.2
0.2
0.1
0.2
0.2
0.1
0.1
0.1
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.2
0.1
0.3
0.1

P-Value
3.8E-4
5.0E-4
2.1E-3
5.1E-3
8.7E-3
1.3E-2
1.3E-2
1.4E-2
1.5E-2
1.5E-2
1.7E-2
1.8E-2
2.3E-2
2.3E-2
2.5E-2
2.6E-2
2.9E-2
4.1E-2
4.5E-2
4.7E-2
5.0E-2
5.1E-2
5.1E-2
6.4E-2
6.5E-2
6.9E-2
7.3E-2
7.8E-2
7.8E-2
8.1E-2
8.3E-2
9.6E-2

Benjamini
5.3E-2
3.6E-2
9.8E-2
1.7E-1
2.2E-1
2.7E-1
2.4E-1
2.3E-1
2.1E-1
2.0E-1
2.0E-1
2.0E-1
2.3E-1
2.2E-1
2.2E-1
2.1E-1
2.2E-1
2.9E-1
3.0E-1
2.9E-1
3.0E-1
2.9E-1
2.8E-1
3.3E-1
3.2E-1
3.3E-1
3.3E-1
3.4E-1
3.4E-1
3.3E-1
3.3E-1
3.7E-1

Table 16. Summary of a subset of genes differentially methylated in patients treated for breast cancer
GENE NAME (ABBREVIATION)
RAD52 homolog (S. cerevisiae)
RAD52
RAD51-like 1 (S. cerevisiae)
(RAD51L1)
phosphoinositide-3-kinase,
catalytic, delta polypeptide
(PIK3CD)
MAD1 mitotic arrest deficient-like
1 (MAD1L1)
retinoic acid receptor, alpha
(RARA)
histone deacetylase 4 (HDAC4)
Janus kinase 1 (JAK1)

v-ets erythroblastosis virus E26
oncogene homolog 1 (avian) (ETS1)
Beta dystrobrevin (DTNB)
Vascular endothelial growth factor
receptor 1 (FLT1)
deoxynucleotidyltransferase,
terminal (DNTT)
tumor protein p63 (TP63)

ubiquitin-conjugating enzyme E2,
J2 (UBC6 homolog, yeast)
(UBE2J2)
DNA (cytosine-5-)methyltransferase 3 alpha
DNMT3A
SMAD family member 3 (SMAD3)

tumor necrosis factor (ligand)
superfamily, member 10
(TNFSF10)
tumor necrosis factor (TNF
superfamily, member 2) (TNF)

Interleukin 1; alpha (IL1A)
Interleukin 18; interferon-gammainducing factor (IL18)

DESCRIPTION OF FUNCTION1
Cell cycle, Interact with DNA recombination protein
RAD51
Cell cycle, Nucleotide and ATP binding

LOCATION2
12: 1,021,255

Apoptosis, Nucleotide and ATP binding, Intracellular
signaling cascade, Transferase

1:9751525

Regulate cell cycle

7:1937325

Cytokine production, immune response, Intracellular
signaling cascade, Zinc ion binding
Regulator of cell proliferation, Cell death , Zinc ion
binding
Nucleotide and ATP binding, Intracellular signaling
cascade, Transferase

17: 38497640

Regulate cell cycle, Cell death, regulator of cell
proliferation, immune response, Cell migration

11:128328656

Zinc ion binding, ion binding
Regulator of cell proliferation, Cell migration,
Nucleotide and ATP binding, Intracellular signaling
cascade, Transferase
Transferase, ion binding

2:25600067
13:28874483

Cell death, regulator of cell proliferation, cell-cell
signaling, Neuron projection, Intracellular signaling
cascade, Zinc ion binding
Nucleotide and ATP binding

3:189349216

Transferase, Zinc ion binding

2:25455830

Transcription factor in the TGF-B pathway,positive
regulator of cytokine production, cell death &
proliferation regulator, regulate cell cycle, immune
responce
Induction of apoptosis, cell- cell signaling, immune
response, Zinc ion binding

15:67458493

Regulate cell cycle , Induction of apoptosis, cytokine
production, regulator of cell proliferation, immune
response, Cell migration, Intracellular signaling
cascade
Regulate cell cycle, cell death, Cytokine production,
regulator of cell proliferation, immune response
Cytokine production, regulator of cell proliferation,
cell cell signaling, involved in behavior, immune
response

6:31543344

1

Functional descriptions obtained from DAVID clustering.
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14:68,286,496

2:240016312
1:65298906

10:98064085

1:1189292

3:172223298

2: 113.531492
11:112013974

Interlaukin 1 family member 6 &
epsilon (IL1F6)
Ataxin 1 (ATXN1)
Huntingtin (HTT),
the myosin heavy chain 10 non
muscle (MYH10)
Myelin basic protein (MBP)

Immune response

2:113763038

Cell death, cell cell signaling, involved in behavior,
neurological system process
Cell death, cell cell signaling, involved in behavior,
Neuron projection, neurological system process
Neuron projection, neurological system process, Cell
cycle, Cell migration, Nucleotide and ATP binding
Cell-cell signaling, immune response, Neuron
projection, neurological system process

6:16299343

2

Chromosome starting nucleotide position
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4: 3076408
17:8377523
18:74690789

Discussion

The current longitudinal study shows that epigenetic alterations are present in peripheral blood
obtained from women with BC following their receipt of chemotherapy. This data indicates the
feasibility of using peripheral blood to assess an individual’s soma-wide cellular response to
different types of treatment regimens. To our knowledge, this is the first longitudinal study
investigating the effect of chemotherapy on methylation patterns in peripheral blood obtained from
women with BC before and after the administration of chemotherapy. We detected 1265
significant DMSs (both increases and decreases in methylation) associated with chemotherapy,
with the majority of changes showing decreases that involved multiple types of sequences. The
observed alterations associated with chemotherapy, included changes in genes involved in the
immune response, transcription regulation, signal transduction pathways, neuronal regeneration,
as well as genes involved in learning and behavior.

The observed acquired alterations in methylation could be directly caused by the chemotherapy.
Alternatively, they could reflect a cascade of cellular reactions that occurred in response to
chemotherapy, such as inflammation. Our use of a longitudinal study design enabled us to make
direct comparisons within individuals to identify alterations associated with the administration of
chemotherapy, without needing to adjust the data for potential confounding effects attributable to
co-factors such as age, race, income, alcohol intake and smoking status, tumor characteristics, and
other comorbidities. However, one biological factor that was adjusted for in the analysis was
changes in the proportions of white blood cells that might arise following chemotherapy, the latter
of which mainly affected the neutrophil cell counts.
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We have identified only one other study in which investigators reported methylation changes
in blood cells following exposure to chemotherapy. In that report, Smith et al. 2014, compared
methylation patterns in peripheral blood mononucleated cells from 22 women treated with
chemotherapy and compared their patterns to those of 39 women who were not treated with
chemotherapy. These investigators detected only 8 DMSs that were significantly associated with
chemotherapy, with each of these 8 sites showing lower methylation values in response to
chemotherapy. Methylation on these sites was also associated with levels of inflammation. Given
that many other factors differed between the treated and non-treated women evaluated in their
study (including but not limited to different genetic/epigenetic backgrounds; environmental
histories; lifestyle histories), their ability to detect differences attributable to chemotherapy was
compromised. Nonetheless, it may not be fortuitous that we also observed decreased methylation
values for 6 of the 8 DMSs identified by the Smith, et al research team [(TMEM49; cg12054453),
(TMEM49;

cg18942579),

(TMEM49;

cg16936953)

(DTNB;

cg25446789),

(SMAD3;

cg05438378) and (cg13518625)]. The increased number of significant DMSs associated with
chemotherapy that was observed in our study as compared to theirs could be due to many reasons.
First, one would expect more than 8 DMSs to be significantly associated with chemotherapy
exposure including sites that are involved in mitosis, cell death, gene regulation, immunity and
inflammation. However, probably due to the small sample size in their study, as well as the
difficulty inherent with detecting differences between women having different genetic/epigenetic
backgrounds; environmental histories; lifestyle histories, as noted above, they were limited in
their ability to detect significant DMSs. Second, they compared treated to non-treated patients,
which is a very big limitation of their study that prevented them from establishing a direct cause
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and effect relationship between the observed differences and the treatment. Lastly, they used the
strict Bonferroni criterion for significance (p<1.03x10-7), while we used the FDR recommended
by Benjamini and Hochberg’s significant at both an FDR of 0.01 and >10% mean within pair
difference). When a more strict significance level was used in our study (FDR of 0.01, >20% mean
within pair difference), only 145 significant DMSs were detected.

The significantly DMSs identified in our study included sites that were localized to genes that
have functions that are congruent with anticipated responses to chemotherapy. These included
clusters of genes involved in the cell cycle, cell death, signal transduction, hemostasis,
transcription regulation, immune response and neurogenesis. Interestingly, we observed
methylation changes involving at least 25 genes having functions related to the immune system,
such as increases in the methylation levels of the tumor necrosis factor (TNF) gene, as well as
decreases in the methylation values for the tumor necrosis factor (ligand) superfamily member 10
(TNFSF10); Interleukin 1; alpha (IL1A); Interleukin 18; interferon-gamma-inducing factor
(IL18); Interleukin 1 family member 6; and epsilon (IL1F6). The DMSs also included sites within
at least 20 genes involved in neurogenesis, learning, memory and behavior, including decreased
levels of methylation for sites localized in genes for Ataxin 1 (ATXN1) & Huntingtin (HTT), as
well as increased methylation values for sites localized to the myosin heavy chain 10 non muscle
(MYH10) and Myelin basic protein (MBP) genes.

Following chemotherapy in our cohort, the distribution of the significant DMSs across the
genome revealed that both increases and decreases in methylation values occurred mainly in sites
localized to “open seas” portions of the genome, but also occurred, albeit in lower percentages, in
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the islands, shores, and shelves. Overall, more decreases in methylation were observed than
increases in methylation.

While there is a paucity of reports of methylation changes in peripheral blood, methylation
patterns present in tumor cells have been more widely studied. Overall, hypermethylation has often
been observed at CpG islands localized to promoter regions of important tumor suppressors, while
hypomethylation has often been observed globally and has been associated with genomic
instability. The distribution of altered DNA methylation that contributes to tumorigenesis has been
found to frequently happen in CpG islands, shores and shelves (Doi et al 2009, Irizarry et al 2009,
Ogoshi et al 2011, Shen et al 2013). Less is known about methylation patterns in peripheral blood
cells obtained from women with breast cancer at baseline. However, based on the limited number
of available studies, global hypomethylation in peripheral blood cells has been observed to be
associated with the presence of BC (Choi et al 2009). Also, methylation of specific loci have shown
promise for use as markers for the presence of BC or an increased risk for developing BC (Iwamoto
et al 2011, Wong et al 2010, Brennan et al 2012, Widschwendter et al 2008).

In summary, chemotherapy for BC, appears to impact the methylation patterns of peripheral
blood cells, with alterations being observed that involve different biological pathways, including
those involved in the immune system, cell death, transcription regulation, neurogenesis, cell cycle
and signal transduction. These study results highlight the importance of further investigation to
assess the role of acquired epigenetic changes in the cellular response to chemotherapy and its
relation with inflammation, and also with the development of PNS.
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These results support the premise that chemotherapy for BC leads to soma-wide alterations in
epigenetic patterns. Further studies confirming these findings and comparing the acquired
epigenetic alterations with acquired PNS following chemotherapy could provide insight about the
biological changes underlying a person’s propensity to develop adverse side effects following
chemotherapy. Ultimately, these types of studies could lead to the development of tests to identify
women most at risk for acquiring cancer or cancer treatment related side effects and could lead to
“personalized medicine” approaches that might improve the quality of their life for BC survivors.
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Chapter 4

Chromosomal Aberrations in Women with Breast Cancer
Copy number aberrations in breast tumor tissues.

Introduction
Breast cancer (BC) is a diagnosis that is shared by many women, since it is one of the most
common cancers diagnosed in females (Siegel, et al. 2014). However, the clinical course
associated with a diagnosis of BC varies markedly among these women. These differences in
outcome have prompted pathologists and other scientists to study the characteristics of BC tumors
in order to improve prognostication and therapy-decision making strategies. In particular, genetic
research has revealed significant differences in the molecular “signatures” of tumors, the latter of
which have served as the basis for improvements in BC classification and management (Polyak,
2011).
The types of genetic abnormalities observed in BC tumors include mutations, copy number
alterations (CNAs), changes in gene expression, and epigenetic alterations. Of the genetic markers,
gene expression profiles in tumors have been most heavily utilized in directing decisions regarding
treatment regimens and prognosis assessments (Byler, et al. 2014; Sinn et al. 2013). The most well
studied BC tumor subtypes are the gene expression intrinsic subtypes, which mostly overlap with
the status of the progesterone (PR), estrogen (ER), and human epidermal growth factor 2 (HER2)
receptors. These subtypes include (but are not limited to); Luminal A (Lum A), Luminal B (Lum
B), HER2+, and triple negative [TNBC]).
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In addition to gene expression changes, copy number alterations, loss of heterozygosity (LOH)
and allelic imbalances are common characteristics of solid tumors, including BC. Studies utilizing
comparative genomic hybridization (CGH) and single nucleotide polymorphism (SNP) arrays
have allowed for enhancements in our ability to identify copy number alterations (CNAs) and
allelic imbalances associated with the molecular intrinsic subtypes (The Cancer Genome Atlas
2012). CNAs in tumors have also been associated with their gene expression patterns (Chin et al.
2006, Pollack et al. 2002, Han et al. 2008).
One challenge investigators have encountered when assessing CNAs (or other genetic changes)
in BC tumors is that these cells do not always proliferate well in vitro, and the tissue culture process
can be associated with the acquisition of genetic/epigenetic patterns that were not present in the
tumor in vivo. An alternative approach is to study formalin fixed, paraffin embedded (FFPE) tissue
that is directly obtained from the tumor. However, FFPE tissue typically has degraded DNA (as a
result of fixation/embedding processes). Also, there is a limited quantity of DNA available for
evaluation from FFPE specimens.

These technological hurdles have thwarted progress in

identifying CNAs associated with clinical outcomes. Nonetheless, a limited numbers of
investigators have successfully reported highly promising results showing relationships between
CNAs in BC tumors and clinical course (Bergamaschi et al 2006, Chin et al 2006, Van et al 2006).
Recently, the utilization of molecular inversion probe (MIP) technology has facilitated the
assessment of CNAs in FFPE tissue (Thompson et al 2011). Using the MIP technology, researchers
studying BC were able to associate tumor CNAs with the patient’s outcome, and have identified
19 CNAs that discriminate recurrence risk in early stage BC (Thompson et al 2011).
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Investigations of the peripheral blood (PB) of patients with cancer, has revealed the presence of
an increase in chromosomal instability and epigenetic alterations that are not only present in the
tumor tissue, but are also observed in the patient’s non-cancerous tissues. Many investigators have
shown the presence of chromosomal anomalies (Barrios et al 1991, Trivedi et al 1998, Gebhart et
al 1993, Pathak et al 1991, Udayakumar et al 1994, Rossner et al, 2005), and high levels of MN
(Santos et al., 2010, Cardinale, et al. 2012) in the PB of patients with solid tumors. However, few
investigators have examined the association between BC - or cancer in general- and DNA
methylation patterns in PB. Also, there is a limited number of investigations published that
compared chromosomal instabilities levels in tumors to those in blood. Therefore, it is of value to
know if PB could be used as an easily accessible surrogate model for detecting genetic aberrations
present in patients with solid tumors or to see if PB values could aid in identifying a person who
has a high risk for developing cancer or the existence of a tumor.

We hypothesis that chromosomal CNAs present in the tumor tissue associate with acquired soma
wide chromosomal changes in other tissues such as the PB. Thus, utilizing the recently available
MIP technology (Oncoscan), chromosomal alterations in the tumor tissue were investigated, in
order to test their associations with soma wide chromosomal alterations in the PB.
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Materials and Methods

Study Participant Ascertainment and Specimen Collection:

For this pilot study a total of 17 women with early stage (I to IIB) breast cancer, who ranged
in age from 41 to 63, were ascertained through the Massy Cancer Center (MCC) at Virginia
Commonwealth University. These women were participants in a larger study that is being
completed by our research team to determine potential associations between chemotherapy
treatment for breast cancer, acquired chromosomal and/or epigenetic alterations, and the womens’
development and persistence of psychoneurological side effects. The inclusion criteria for the
larger study was : (1) 21 years or older; (2) diagnosis of early stage breast cancer with a scheduled
visit to receive chemotherapy; and (3) female gender (males were excluded since too few male
participants were available for study). Exclusion criteria included: (1) a history of previous cancer,
or chemotherapy; (2) a diagnosis of dementia; (3) active psychosis; or (4) a history of immunerelated diagnoses (e. g. multiple sclerosis; systemic lupus erythematosus). Women who provided
their informed consent (VCU IRB #HM 13194), to participate in the larger, parental study were
recontacted to determine if they were interested in having tissue from their tumors evaluated in
this pilot study. Following their informed consent, the tumor specimens studied were obtained
from the pathology lab via the Tissue & Data Acquision & Analysis Core (TDAAC) within the
Department of Pathology at VCUHS. Peripheral blood specimens were collected by venipuncture
or an existing access device prior to the initiation of chemotherapy. All specimens were coded
prior to ensure that the cytogeneticists were unaware of the clinical history of each participant at
the time of sample processing and evaluation.
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Macrodissection of tumor tissue and tumor DNA extraction:
Tissue sections were prepared and reviewed by a pathologist, who identified the areas of the
tissue that contained tumor to guide the macrodissection of the specimens. In addition to an H&E
slide denoting the location of tumor, the laboratory received 5 unstained slides from the adjacent
tissue. Deparaffinization was performed using the Protocol SafeClear (Xylene substitute from
Fisher). Each of the deparaffinized, unstained slides was then aligned on top of the marked
matching H&E stained slide. The tumor area was then marked from the back of the slide. A
disposable blade was used to remove the non-tumor tissue. The remaining marked tumor tissue
was scrapped off and transferred into a labeled 2.0 µl Sarstedt tube. FFPE Genomic DNA
extraction (including tissue lysis, DNA purification and elution) was performed using the QIAamp
DNA FFPE tissue kit, as recommended for the Oncoscan Assay following the manufacturer’s
protocol. Quantification of the eluted FFPE DNA was done using the Qubit ds DNA HS Assay Kit
according to the manufacturer’s instructions.
Tumor tissue copy number and somatic mutation analyses:
A total of 6 µl of DNA, at a concentration of 12ng/ul, was prepared for the processing of the
OncoScan FFPE Assay (Affymetrix). This array allows the sample(s) to be interrogated for
genome-wide copy number alterations, genome-wide LOH, and targeted mutations. This assay,
which utilizes molecular inversion probe (MIP) technology, provides CNA assessments of
approximately 900 cancer-related genes, with a resolution that ranges between 50kb-125kb. In
addition, it provides genome-wide coverage with a resolution that ranges between 300-380 kb. The
array also allows for the detection of 74 actionable somatic mutations from 9 different genes
(BRAF, KRAS, EGFR, IDH1, IDH2, PTEN, PIK3CA, NRAS, TP53). Genome-wide LOH can
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also be evaluated usng this platform (with a resolution of 3MB-10MB). However, we elected to
exclude the assessment of LOH in this pilot study since we did not have data for paired normal
and tumor specimens.

All aspects of the OncoScan assay were performed following the

manufacturer’s instructions.
Peripheral Blood Chromosome Instability Methodology:
Baseline levels (prior to the administration of therapy) of chromosomal instability present in
peripheral blood were quantified for each pilot study participant using the cytokinesis-block
micronucleus (CBMN) and cytome assay (Fenech, 2006). A micronucleus (micronuclei) (MN)
is(are) a small chromatin containing structure(s) juxtaposed to a parent nucleus. The CBMN assay
was selected for the chromosomal instability assessments because it allows for: (1) the
quantification of both numerical and structural cytogenetic findings; (2) the analysis of a large
number of cells, thereby enhancing one’s ability to detect even low levels of instability; and (3)
minimization of in vitro growth selection (only 1 round of cell division is completed in vitro) and
minimization of technical artifacts due to processing (for example, the CBMN assay does not show
chromosome “loss” due to cell breakage at harvesting or slide making, which can occur when
assessing metaphase chromosomes).

Leukocytes, which were isolated using Histopaque-1077 (Sigma), were established in culture
according to the protocol of Fenech (1993). Briefly, following their mitogenic stimulation using
phytohemaglutinin (PHA), lymphocytes were arrested at cytokinesis by adding cytochalasin B to
the cells 44 hr after their culture initiation. The cells were harvested 72 hours after culture initiation
and slides prepared (2 per specimen) as described previously (Leach and Jackson-Cook, 2001).
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Micronuclei, buds, and/or bridges were visualized following giemsa staining (4% Harleco
Giemsa solution) and identified according to the criteria established by Fenech (2006)(Figure 3).
The proportion of abnormalities was calculated by adding the values obtained from the two
replicate scores (1000 binucleates were evaluated from each of two slides for a total of 2000
binucleates per study participant). The total number of binucleates with abnormalities was then
divided by the total number of binucleates scored.

Data analysis:
The OncoScan Console 1.0 software was used to determine that the experimental processes met
or exceeded vendor established quality control standards. The OncoScan Nexus express software
was used to identify CNAs, LOH, and somatic mutations in the tumor samples. Statistical
Pearson’s correlation comparisons between tumor CNAs and peripheral blood chromosomal
instability were completed using the R programming environment (R Development Core Team,
2011).
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Figure 9: Log 2 ratio and B allele frequency plots for sample 2005.
CNAs were detected for chromosomes 15 (a loss at 15q); 16 (loss); 18 (a loss [monosomy]) and 20 (a gain [trisomy]).
The tumors were estimated to be present in approximately 70% of the cells evaluated.
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Results

Tissue amenable for use in the OncoScan array was available for 14 of the 17
participants who provided consent to have analyses completed for their tumor specimens,
with three cases having an insufficient amount of residual tissue containing tumor that was
available for assessment in this pilot study. The amount of DNA required for the OncoScan
assay was successfully obtained from 11 of these 14 tumor tissues, with the cases having
an insufficient amount of tumor all being derived from fine needle aspirates. Of the 11
cases for which DNA was successfully obtained, a total of 10 specimens yielded results
that could be interpreted, with one sample having an array result that could not be
unequivocally evaluated (possibly due to tumor heterogeneity and/or DNA degradation).
One of these 10 tumor specimens was from a woman who died within 2 years following
the initiation of chemotherapy (case 2001).

The specimens that were evaluated were all obtained from participants who were
diagnosed at early stage BC (I-IIB). The mean age of the participants was 50 years old.
The age, race, and tumor characteristics of the participants from whom the 10 specimens
were evaluated using OncoScan are summarized in table 17.

Summaries of the CNAs, including amplifications, and the somatic mutations occurring
in each patient are shown in tables 2-4. CNAs were detected in all of the 10 breast tumor
tissues evaluated, with the number of events varying from tumors to tumors (Table 18).
Genome-wide CNAs for each patient, and collectively for the pilot study cohort, are shown
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in Figure 10. The most frequently observed CNAs were: Gains at 1q (70%), and 8q (70%),
and losses at: 8p (70%), 17p (70%), 17q (60%), 18q (60 %), 13q (50%), and 22 ( 50%).
As expected, since all the tumors were evaluated from females, loss of Y chromatin was
observed for all tumors (far right of Figure 10) The most commonly observed pair of
aberrations was loss of 8p and gain of 8q. High copy gain amplifications and homozygous
losses are summarized in Table 19. Amplifications of regions including well-known
oncogenes were observed, such as the ERBB2, MYC, and ERBB3. Amplifications (high
copy [at least 4 copies] gains tended to be more frequent in HER2+ tumors (patients: 2001,
2011, 2028 ). Moreover, homozygous deletions of well-known tumor suppressors such as
the RB1 were also detected.

In addition to evaluating CNAs, an assessment of targeted somatic mutations was also
completed for the tumors (Table 20). Somatic mutations were detected for 6 of the 9 genes
targeted in this array. A total of 7 of the 10 tumors had mutations within the TP53 gene; 6
had mutations in KRAS gene; 6 had mutations in the EGFR gene, 5 had mutations in the
NRAS gene, 2 in the PTEN gene and 1 in the PIK3CA gene. Mutations involving the
KRAS and at TP53 were found in 100% of ER+ patients, but in only in 25% of ER- patients
(p=.03). Also, the total number of somatic mutations detected was higher in HER2+ tumors
(HER2+ and luminal B) than HER2 negative tumors (luminal A and triple negative)
(p=0.04).

When CNAs were compared on the basis of the tumors’ intrinsic subtypes, significant
differences were detected (Table 21). Gains involving chromosomes: 3 (q26.31 - q27.1);
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10 (p11.22 - p11.21) and (q22.1); 16 (p13.3); and 22 (q13.1 - q13.2) were found in 100%
of HER2+ tumors, and 0% of the other three subtypes (TNBC, Lum A, and Lum
B)(p=0.02). Also, gains at 20q13.31 were seen in 100% of the TNBC tumors, but 0% of
the other three subtypes (p=.02). Losses at 17p13.2 were present in the two HER2+ tumors,
the 3 Lum B tumors , and 1 out of the 2 TNBC tumors, but were not present in any of the
three Lum A tumors (p=0.03).

As expected, ERBB2 was amplified only in HER2+/Luminal B tumors. However, the
amplification was not detected in 2 out of the 5 HER2+/Lum B patients (Patients 2001 &
2021). Tumors were also subdivided based on their estrogen receptor (ER) status. Losses
involving chromosomes 12 (q13.13); 15 (q24.1 - q24.2) & (q24.3 - q25.1); and 17 (q21.32
- q21.33) & (q24.2 - q24.3) were present in 75% of patients with ER- status, but in none of
the ER+ tumors (p= .03).

The tumors included in this study were determined to be either grade 2 or grade 3.
Significant differences in the CNAs present in the grade 2 compared to grade 3 tumors
were detected, with losses involving the proximal short arm of chromosome 4 (4p14; 4p13;
and/or 4p12), the proximal short arm of chromosome 7 (7p11.2), and the proximal long
arm of chromosme 17 (17q12) being present in 75% of the grade 3 tumors, but in none
(0%) of the grade 2 tumors (p=0.03). Moreover, when groups were compared based on the
stage of the tumor, gains at 20q13.31 were found in 100% of stage I tumors, but in none
(0%) of the stage II (A or B) tumors (p=0.02). In addition, high copy gains at 8p11.22-
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p11.21 were seen in 100% of stage IIB tumors, but in none (0%) of the lower stage tumors
(I & IIA)(p =0.02), suggesting that this finding is associated with (or acquired in) more
advanced tumors.

Comparisons were also completed to determine if baseline peripheral blood
chromosomal instability levels were correlated with the CNAs or somatic mutations
present in the women’s tumors. While a trend of an association between MNF in PBCs
and tumor mutations, the percent of the tumor genome changed, and tumor cells with
amplification of MYC was observed, none of these associations were significant. A
significant association was between MN and homozygous loss (p =.04) . (Table 22)
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Table 17: Participants ‘ demographic and tumor characteristics.
Subject ID
2001
2005
2010
2011
2012
2018
2021
2026
2028
2031

Age

Race

Grade Stage

ER+

PR+

HER2+

Subtypes

56
51
41
41
63
52
58
47
43
48

AA
AA
AA
AA
C
AA
AA
AA
C
C

2
2
2
2
3
2
3
2
3
3

N
N
Y
Y
Y
Y
Y
N
Y
N

N
N
Y
Y
N
Y
Y
N
N
N

Y
N
N
Y
N
N
Y
Y
Y
N

HER2 +
Triple negative
Luminal A
Luminal B
Luminal A
Luminal A
Luminal B
HER2 +
Luminal B
Triple negative

IIB
I
IIA
IIB
IIA
IIA
IIA
IIA
IIA
I
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Table 18. Number of CNAs in tumors

Patient
2001
2005
2010
2011
2012*
2018
2021*
2026*
2028*
2031*

Gains
29
1
2
11
16
6
3
18
4
18

High copy gains
(4 or more)
38
0
1
10
0
13
1
3
14
5

1 copy
Loss
19
7
5
17
25
16
10
14
11
19

Homozygous
Loss
2
0
1
0
0
0
2
0
0
0

Total % Genome
CNA
Changed
88
31.73
8
6.42
9
10.24
38
13.68
41
44.63
35
25.16
15
22.4
35
26.97
29
10.47
42
45.96

* Tumors demonstrated patterns consistent with tumor heterogeneity.
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MNF
0.034
0.039
0.031
0.049
0.044
0.061
0.039
0.063
0.067
0.064

Figure 10: Copy number alterations (CNAs) in the 10 tumors evalauted.
(Red) indicates loss & (Blue) indicates gain. The uppermost plot shows the composite of findings observed in all participants. The lower plots
show the findings for each tumor (identified by study participant number).
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Table 19: Amplifications and homozygous losses occurring in tumors
ID

HCG*

Range of HCG

Important Oncogenes included

2001

38

(4-9 copies)

2005
2010
2011
2012
2018
2021

0
2
10
0
13
1

6 copies of MYC, 4 copies of ERBB3, 5
copies of RAD5IB, 4 copies of
MAPK13 &14

4 copies
(4-8 copies)

4 copies of HORMAD1
6 copies of ERBB2

(4-23 copies)

4 copies MYC , 13 copies CCND1
4 copies MYC

0
1
0
0
0
2

2026
2028
2031

3
14
5

10 copies of ERBB2, 4 copies MYC
11 copies of ERBB2
4 copies MYC

0
0
0

(4-10 copies)
(4-11 copies)
(4-7 copies)

* HCG= High copy number gain
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Homozygous
loss

2

chr/gene

RB1

1p13.2

17p12,
17p13.1

Table 20: Mutations detected in tumors
Patient

Type

High confidence

2001

Missense

KRAS

2005

None

None

2010

Missense

NRAS, EGFR, KRAS, TP53

2011

Missense
Nonsense
In-frame
Deletion in
Frame

NRAS, EGFR , KRAS, TP53
PTEN
EGFR
EGFR

2012

Missense

TP53

2018

Missensse

KRAS, TP53

2021

Missensse

NRAS, TP53

2026

Missensse
Frame-shift

NRAS, PIK3CA, EGFR, KRAS, TP53
PTEN

2028

Missensse

NRAS, EGFR, KRAS, TP53

2031

Missensse

EGFR, TP53
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Table 21 : Significant CNAs detected in tumors based on subgroup comparisons.
Chromosome

Event

Frequency in other groups

p-value

Gain
Gain
Gain
Gain
Gain

Frequency of occurrence in
the prominent group
100 % of HER2+
100 % of HER2+
100 % of HER2+
100 % of HER2+
100 % of HER2+

3 (q26.31 - q27.1)
10(p11.22 - p11.21)
10 q22.1
22(q13.1 - q13.2)
16 p13.3

0% in (TRNG, Lum A, & Lum B)
0% in (TRNG, Lum A, & Lum B)
0% in (TRNG, Lum A, & Lum B)
0% in (TRNG, Lum A, & Lum B)
0% in (TRNG, Lum A, & Lum B)

0.02
0.02
0.02
0.02
0.02

20q13.31

Gain

100% of TRNG

0 % in (HER2+, Lum A, & Lum B)

0.02

17p13.2

Loss

85% of(TRNG,HER2+,Lum B)

0% of Lum A

0.03

17p13.2

Loss

100% of (HER2+ & Lum B)

20% of (TRNG and Lum A)

0.05

12 q13.13
15 (q24.1 - q24.2)
15 (q24.3 - q25.1)
17(q21.32 - q21.33)
17 (q24.2 - q24.3)

Loss
Loss
Loss
Loss
Loss

75% of ER75% of ER75% of ER75% of ER75% of ER-

0% of ER+
0% of ER+
0% of ER+
0% of ER+
0% of ER+

0.03
0.03
0.03
0.03
0.03

4 p14
4 p13
4 p12
7p11.2
17q12

Loss
Loss
Loss
Loss
Loss

75% of grade 3
75% of grade 3
75% of grade 3
75% of grade 3
75% of grade 3

0% of grade 2
0% of grade 2
0% of grade 2
0% of grade 2
0% of grade 2

0.03
0.03
0.03
0.03
0.03

20q13.31
8p11.22-p11.21

Gain
HCG

100% of stage I
100% of stage IIB

0% of stage IIA &IIB
0% of stage I & IIA

0.02
0.02

17 q12
17q25.1

Loss
Gain

100% of Caucasians
100% of Caucasians

0% of AA
14% AA

0.008
0.03
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Table 22: Correlations between MNF in the peripheral blood and CNAs
and mutations in the tumor tissue
Type of CAN
Gain
>2 copy gain
one copy loss
Homozygous loss
Total (CNA)
% of genome changed
Mutations
Amplification of MYC

Correlation with
MNF
0.066
-0.054
0.255
-0.651
0.047
0.221
0.4
0.25
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p-value
0.86
0.88
0.48
0.04
0.90
0.53
0.34
0.49

Table 23: Most frequently observed CNAs in patients with BC
Most frequently observed CNAs

References

Gains at 1q (35%), 8q (35%) , 11q (26%), and 16p (14%)
Losses at 4q (58%), 5q(54%), 6q(43%), 8p(48%), and 14 q(48%).

Bergamaschi et al 2006

Gains at 1q (55%), 8q (41%), 16p (40%), 17q (28%), 20q (19%),
Rennstam et al 2003
and 11q (16%).
Losses at 13q (27%), 16q (22%), 8p (18%),
most frequent pairs: -8p/+8q, +17q/+20q, and -4q/-13q
Gain at 1q (64.8%), 8q (61.4%), 17q (50.0%), 20q (33.0%), 3q Weber-Mangal et al
(20.5%), 1p (17.0%), 5p (17.0%) and 15q (17%)
2003
Loss at 8p (19.3 %), 11q (11.4%), 16q (11.4%), 17p (11.4%) and
18q (10.2%).
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Discussion

The CNAs detected in the small number of tumors evaluated for this pilot study were
consistent with previously reported findings using chromosomal banding, chromosomal array
CGH, and/or microarray methodologies. For example, the most frequently observed CNAs
seen in the tumors assessed in this pilot study included: Gains at 1q, 8q, and 8p, and losses in
8p, 17p, 17q, 18q, 13q, 22q, 4p, 5q, 11q, and 16q (Figure 10). Most of these regions have also
been recognized as areas of imbalance seen most often in BC tumors evaluated by other
investigators (Thompson et al 2011, Bergamaschi et al 2006, Weber-Mangal et al 2003,
Rennstam et al 2003)(Table 23). In agreement with our observations, losses at 8p and gains
at 8q are one of the most commonly observed pairs of aberrations seen in BC tumors
(Rennstam et al 2003), and are likely to reflect the presence of an isochromosome/isodicentric
chromosome for the long arm of chromosome 8.

Our assessments of CNAs with tumor subtype also showed areas of agreement with
the results of previous investigators. For example, we observed losses at 17p13.2 (which is
located near the TP53 gene but did not include it) in 6 of the 10 tumors analyzed, but none of
the 3 luminal A tumors showed this loss. Other investigators have also reported a higher
frequency of 17p13.1 loss in luminal B and HER2+ tumors compared to luminal A and triple
negative tumors. (Thompson et al 2011).

Interestingly, the tumor that was obtained from patient 2001, who died within 2 years
following the initiation of her chemotherapy, is the only tumor evaluated that showed multiple
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regions of high copy gains, including amplification of well-known oncogenes such as MYC,
ERBB3, RAD5IB, MAPK13, MAPK14. This tumor also contained a homozygous deletion
of the RB1 gene, losses involving 8p22 and Xp21, and a gain at 10p11.2. Many of these
aberrations have been reported to be associated with a poor outcome.
As expected, ERBB2 was amplified only in the HER2+ & Lum B tumors. However,
amplification for HER2 that was detected in diagnostic testing using FISH methodology was
not detected in 2 of the 5 tumors evaluated with the OncoScan array platform (Patients #2001
& 2021). Tumors for patient 2021 showed high levels of heterogeneity in the microarray test.
Thus, it is possible that the proportion of cells having amplification in the section of residual
tissue available for evaluation was not large enough to allow for its detection above the
“noise” present in this specimen. Indeed, the results of the Oncoscan assessment for this case
showed at least two cell populations, with one of them being present in a low proportion of
cells. An additional factor that might have contributed to the observed discrepancy between
the FISH and microarray test results was the loss of chromatin from the short arm and
centromeric region of chromosome 17, which is a finding that was noted in both discrepant
cases. The OncoScan platform has been reported to allow for the detection of false positive
HER2 FISH results, the latter of which have been observed for HER2 to control probe
(localized to the centromeric region of chromosome 17) ratios that are greater than or equal
to 2 due to a relative decrease in centromeric probe signals rather than in increase in HER2
signals, which is a finding that can be undetectable in a tumor having a near-tetraploid
complement.

Clearly, this observation requires further investigation through carefully

designed clinical validation studies before the OncoScan platform is used for diagnostic
testing.
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While the number of tumors evaluated in this study was small, the tumors analyzed
included representatives from each of the 4 intrinsic tumor subtypes. Although preliminary,
the results of this study suggest that the evaluation of CNAs could provide additional
information to facilitate the recognition of tumor subtypes. For example, gains at 3q26.31 to
3q27.1; 10q22.1; 16p13.3; and 22q13.1 to 22q13.2 were found only in two patients, both of
whom were both HER2+. To our knowledge, none of these CNAs have been previously
reported to be specifically associated with HER2+ tumors. Our observation of gains of
20q13.31 has also been detected in BC tumors by other investigators (Weber-Mangal, et al,
2003; Thompson, et al.,2011). However, the association of gains of 20q with tumor type is
not consistent, with our data showing this finding only in patients diagnosed with TNBC,
while other investigators have reported associations between gains for 20q in HER2 + and
Lum B tumors (Thompson et al. 2011). Thus, the diagnostic and prognostic relevance of this
finding appears to be limited.

No clear trend for an association between MNF in the peripheral blood and copy number
alterations or mutations in the tumor was detected. The only significant correlation observed
was between MN in PB and homozygous loss in the tumor ( r= -0.6 , P=0.04) Table (6).
However, this observation is based on only three homozygous deletions. Thus, this result
should be interpreted with caution and the potential associations confirmed using a larger
sample size.
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In conclusion, the results of this “proof of principle” study support the use of the OncoScan
genome-wide array for assisting with the recognition of differences between tumors.
However, our data are too preliminary to determine if the CNAs recognized will lead to
improvements in categorization or prognostication of BC tumors. Also, our study results
showed no clearly significant associations between MNF in PB and any of the CNAs changes
in the tumor, with the exception of homozygous deletions.
Through our future evaluation of a larger number of tumor specimens we hope to be able
to answer the following questions: Could CNAs in the tumor tissue associate with CNAs and
methylation patterns in WBCs? Do CNAs in the tumor tissue associate with the acquisition
and/or persistence of adverse side effects related to chemotherapy? Could alterations observed
in peripheral blood cells be used as early detectors of carcinogenesis in the tumor tissue? The
use of WBCs as early detectors of cancer or as early predictors of an outcome is a concept
that is worthy of more investigation.
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Chapter 5

Conclusions

The primary goal of the current study was to investigate the biological basis for the
development of psychoneurological symptoms (PNS) associated with chemotherapy, or the
cancer itself, in women treated for breast cancer (BC). A longitudinal study was designed to
investigate chromosomal/epigenetic changes in peripheral blood cells collected from women
with BC at 5 time points and to examine the role of chromosomal alterations present in the
tumor tissue at baseline.
The following conclusions were attained for the study aims that were examined.
Aim A) Determine the frequency of acquired chromosomal instability present before
and

following

treatments

and

investigate

its

relationship

to

the

development/persistence of PNS.

To date, micronuclei frequencies (MNF) have been scored for a total of 73 women at 4 times
points, with 43 of these women also having data available for a fifth time point (2 year followup). The data presented in this dissertation included only the 4 time points that have been
statistically analyzed. The final optimized statistical model identified 8 variables that had a
significant predictive association with MN/cytome abnormality frequencies. These variables
included:
(1) The time point at which the specimen was collected (p<0.0001)
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(2) The type of chemotherapy treatment (p=0.0463)
(3) Exposure to radiotherapy (p=0.0004)
(4) Race (p=0.0037)
(5) Having a luminal B tumor categorization (p=0.0182)
(6) Having a triple negative tumor categorization (p=0.0446)
(7) Total perceived stress levels (p=0.0123)
(8) Cognitive flexibility domains (p=0.0238)

Decreases in MNF were observed 1 year following treatment, but did not return to baseline
levels. At 2 years following chemotherapy, the preliminary results including a subset of
women at time point 5 shows that MNF declined following the completion of all treatments.
However, women showed variability, with levels of MN returning to baseline in a subset of
women but remaining high in other women.

Aim B) Determine genome-wide epigenetic changes present at baseline and following
chemotherapy to determine if methylation alterations are induced in peripheral blood
cells following treatment.

To date, DNA methylation data has been collected for 69 women (at time points 1 & 2),
and for 57, 45, and 10 women at time points 3, 4 and 5 respectively. The present dissertation
includes results that have been statistically analyzed for 67 women before and during
chemotherapy (T1 & T2). The following results have been concluded:
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1) The results indicate that epigenetic changes associated with chemotherapy are acquired in
peripheral blood.
2) A total of 1265 sites showing significant differential methylation after chemotherapy were
detected at (FDR= 0.01 and >10% mean within pair difference). These sites included CpGs
located within genes that are involved in the cell cycle, transcription regulation, cell death,
signal transduction, neurogenesis, and in immune response.
3) Acquired decreases in methylation were more frequent than acquired increases in
methylation.
4) Acquired alterations in DNA methylation were distributed across different genomic
sequences, with the majority of changes occurring in the open sea sequences.

Aim C) Detect CNV present in BC tumor tissue and determine its relationship to
peripheral blood MNF and methylation patterns at baseline.

Only 10 samples were included in this preliminary investigation. Not surprisingly, due to
the small sample size, no clear associations were detected between MNF in blood and CNVs
in tumors. However, the CNVs detected in the small number of tumors analyzed using the
new OncoScan microarray platform were consistent with those previously reported in breast
cancer tumors, thereby confirming that the genetic make-up of our study participants’ tumors
are representative of those observed in larger groups who were evaluated using alternative
methods (classical chromosomal banding, chromosomal array CGH, and/or other microarray
platforms).
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Overall, our results support the primary hypothesis of this study, which states that in
response to chemotherapy, biological changes arise in somatic tissue (PBCs) leading to
genomic and/or epigenetic alterations that potentially contribute to PNS. Each of these
genomic/epigenetic factors, acting either singly or in concert, could contribute to the
development/ persistence of PNS since they would provide a means for “remembering” the
biological effects after chemotherapy and have plasticity to explain responsiveness to
environmental exposures (as well as G x E interactions). They also have the potential for
reversibility, with the latter attribute being important for the potential development of
therapeutic interventions.
This data also indicates the feasibility of using peripheral blood to assess and monitor an
individual’s soma-wide cellular response to different types of treatment regimens. Further
investigation and continuation of this study, including all patients at all time points, could
provide insight about the biological changes underlying a person’s propensity to develop
adverse side effects following chemotherapy, including but not limited to PNS. Ultimately,
these types of studies could lead to the development of tests to identify women most at risk
for acquiring cancer or cancer treatment-related side effects and could lead to “personalized
medicine” approaches that might improve the quality of life for BC survivors.
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Chapter 6

Methylation patterns in fetuses in fetu having disorganized development compared to
those in their identical liveborn triplet

Fetuses in fetu (FIF) is a rare condition in which the growth of a twin/triplet erroneously
occurs within the body of a co-twin/triplet. The incidence is estimated to be 1/500,000 births
(Hoeffel et al., 2000). While the term fetus in fetu has been reported by Meckel in 1800, and
the first case was been cited in 1809 by Young, a specific diagnostic criteria to distinguish it
from teratoma was not developed until 1935 when Willis (Willis, 1935) defined the diagnosis
of FIF by the presence of a vertebral column, which is often surrounded by other organs. In
1956, Lord suggested that in addition to the presence of the vertebral axis, an appropriate
arrangement of other organs and limbs is required. The majority of cases are found to occur
as an abdominal mass (Hoeffel et al., 2000). However, reports of FIF present in the sacrum,
pelvis, liver, lungs, spleen, lymphnodes, pancreas, adrenal gland, scrotum and in the cerebrum
have also been described (Gangopadhyay et al 2010, Heuer et al 2008, Escobar et al, 2008).

A mechanism for FIF is that they arise from the inclusion of a diamniotic monochorionic
monozygotic twin in its co-twin due to the unequal division of the inner cell mass during
embryogenesis (Lord, 1956, Beaudoin et al 2004). An alternative theory, termed the teratoma
theory, states that the mass found in the fetus is a highly-organized, well differentiated
teratoma (Magnus et al, 1999; Gilbert-Barness et al., 2003).
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To gain insight about the embryonic origin of FIF Miura et al (2006) completed genotyping
studies for two different cases of FIF and also looked at the methylation status at the human
IGF2-H19 locus. They concluded that the genotypes of both cases of FIF were identical to the
genotypes of the host infant, providing support for the monozygotic twin theory of
development. They further conjectured that the implantation of the FIF occurred during the
process of methylation establishment in the first case (based on differing patterns of
methylation in the multiple clones evaluated), while it happened after the establishment of
methylation in the 2nd case.

In 2012, Huddle et al published a case report on rare intraventricular fetuses in fetu. The
case was diagnosed following both Willis’ and Lords’ criteria. Two fetiform structures were
connected to the host’s circulation by a vascular pedicle. Both masses were anencephalic and
had a vertebral column with well-formed limbs. The two fetuses had other organs including
CNS, gastrointestinal, and genitourinary tissues along with other less commonly observed
organs such as the thymus, salivary glands, tooth buds, and adnexal structures. The organs
were in a relatively correct anatomic arrangement to one another. Karyotyping and genotyping
(using a SNP array analysis) on tissues obtained from the two fetuses and the host confirmed
that the three structures were genetically identical females with a normal chromosomal
complement. Thus, this case supports the monozygotic twin theory. These FIF also provide
a unique opportunity to recognize genes that undergo methylation alterations during
embryogenesis since they share identical genotypes, albeit in very different development
environments. Therefore, the primary aim of this study was to determine the genome-wide
DNA methylation patterns in the two fetuses in fetu and to compare those patterns to the
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patterns seen in their genetically identical host triplet, the latter of whom showed normal
development other than the brain malformations that resulted from the management of the
FIF (Huddle, 2012).
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Materials and Methods

Subjects and sample collection:
The patient was a female child of Vietnamese ancestry who was initially ascertained following
an ultrasound study at 37 weeks’ gestation, the latter of which showed dilated lateral ventricles
and a possible aqueductal stenosis. At birth, a head CT showed significant ventriculomegaly
with a midline intraventricular sof-tissue mass having ossified stuctures suggestive of a
fetiform mass. At 3 months of age, the child presented with neurological symptoms that
necessitated the need for a craniotomy to remove the FIF masses. More details about the
clinical findings in the patient and the fetus in fetu are provided in the case report by Huddle
et al, (2012). At the time of surgery, a blood sample was collected from the child (host), and
biopsies were collected from the FIF tissues. Tissues from the FIF were immediately
established in culture, using standard procedures, to allow for the completion of the requested
chromosomal studies. Genomic DNA for the FIF was extracted from the cells established in
monolayer cultures using the Puregene DNA Isolation Kit (Qiagen) according to the
manufacturer’s methodology. Genomic DNA was isolated directly from the whole blood
sample collected from the host child using this same procedure (Puregene DNA Isolation Kit
by Qiagen). Requests to collect a skin biopsy from the host child (to allow for a more direct
comparison of tissue types between the FIF and their liveborn triplet) were unsuccessful.
Therefore, to assist with recognizing methylated regions that varied due to tissue-type
differences, DNA was also isolated from the fibroblast-like cells from an amniotic fluid
specimen. Also, to allow for comparisons of the methylation patterns seen in the FIF to those
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present in multipotent cells, DNA was isolated from 3 unrelated breast adipose-derived
mesenchymal stem cells (bASC1, bASC2, bASC3)(Sachs, et al., 2012)

Genome-wide DNA methylation pattern:
The 450K HumanMethylation Chip (Illumina) was used for determining genome-wide
DNA methylation patterns in: (1) the fetuses in fetu; (2) the host child (peripheral blood); (3)
3 multipotent breast adipose-derived stromal cell lines; and (4) cultured cells from an amniotic
fluid specimen. Following bisulfite conversion, the genomic DNA was hybridized to the 450K
HumanMethylation Chip according to the manufacturer’s protocol (Illumina).

Data visualization and statistical analysis:
The Genome Studio Methylation Module (Illumina) and R (R 2.15.1) were used for data
visualization and statistical analysis.

The minfi package from R was used for data

normalization, Pearson’s correlations estimation, and for Bean and density plot creations. To
determine the specific CpG sites that were differentially methylated between the child and the
two FIF the following strategy was followed: for each sample, bead level data were read into
the R programming environment. After excluding beads having a negative or zero intensity
in either the red or green channel, raw signal intensities for the Methylated and Unmethylated
Infinium Type I designed beads were retained and for Infinium Type II designed beads,
proportion methylated was calculated as =(Red intensity)/(Red intensity + Green intensity)
=[0,1]. Prior to applying the logit transformation, any  values equal to 0 were imputed to
be 0.0001 while  values equal to 1 were imputed to be 0.9999. Thereafter, a logit
transformation was applied to the  values to promote normality.
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For Infinium design type I beads, the logarithm of the signal intensity was modeled using
an analysis of variance (ANOVA) where probe type (Methylated or Unmethylated), subject
(Child, FiF), and their interaction was included as fixed effects in the model. The p-values
from the two independent ANOVA models were then combined using Fisher’s method for
combining p-values. The false discovery rate was estimated using the combined p-values
based on the Benjamini and Hochberg method (1995). CpG sites having both an FDR<0.01
and a ||  0.20 were considered significant. For Infinium design type II beads, the statistical
analysis was restricted to bead types having at least two observations in all three samples. For
each FiF and bead type, a two-sample t-test was performed to compare the logit-transformed
 values between group (Child versus FiF). Again, Fisher’s method was used to combine pvalues resulting from the two independent t-tests and then Benjamini and Hochberg’s method
was used to estimate the false discovery rate.
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Results

Bean plots for the beta values are shown in Figure 11 for each of the 7 specimens.
The greatest level of variation was observed for hypermethylation states. While the
methylation patterns of the 2 genetically identical FIF closely resembled one another, their
patterns (especially hypermethylation) varied from those observed for the other specimens,
showing patterns that more closely resembled those of the multi-potent stem cells, than their
genetically identical “host” triplet, or the tissue comparable amniotic fluid specimen.
Interestingly, the multi-potent adipose-derived stromal cells that were derived from 3
unrelated individuals showed similar patterns, suggesting that the methylation status of these
cells was more closely associated with their multi-potent characteristic than their genotype.

The density of the beta values is shown in Figure 12 for each specimen. The samples
tend to cluster into 3 groups: (1) the child and amnio case (highest density of hypermethylated
loci); (2) the fetuses in fetu (mid-group); and (3) the multi-potent adipose-derived stromal
cells (lowest densities for hypermethylated sites)

Genome-wide methylation states were highly correlated between the fetuses in fetu (Figure
13 A). However, the methylation states of the fetuses in fetu more highly correlated to the
patterns of the multi-potent adipose-derived stromal cell lines than to those of the host child
or the amniotic fluid case (Figure 13).
A genome-wide sample and locus cluster analysis confirmed the overall similarity in
methylation patterns between the genetically identical (FIF), and the similarity between the
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stem cells (dendograms on right based on complete data set). The observation that the host
child was more closely related to the amniotic fluid case than the fetuses in fetu, suggests that
the observed patterns reflect factors other than just genotype or tissue type. (Figure 14)
Over the 485,764 sites interrogated, clusters of similar patterns were observed that were:
(A) consistent for the FIF and host child, but not the other specimens (likely to be genotype
driven); (B) limited to the FIF; (C) common for the FIF and the multi-potent cells but not the
child/amniotic fluid cells (influenced by environmental/developmental cues); (D) distinct for
the multi-potent cells; (E) distinct to peripheral blood (shown) or amniotic fluid cells (not
shown); or (F) similar across all specimens. The results of a cluster analysis that was
completed for the entire data set 9 (Figure 14) confirmed the similarity in patterns between
the FIF, with the greatest variation in patterns being observed between the genetically
identical host child blood specimen and the FIF samples.

An analysis to identify specific CpG sites that were differentially methylated in the FIFs’
and the child’s genomes, based on the Infinium design type I beads, revealed 12,187
significantly differentially methylated CpG sites (using a false discovery rate [FDR] <0.01
and a ||  0.20). For the Infinium design type II beads, a total of 56,090 CpG sites showed
significantly different methylation values (FDR<0.01 and a ||  0.20).
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A)

B)

C)
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D)

Figure 13: Correlations for FIF. Genome-wide methylation states were highly correlated
between the fetuses in fetu (A). When comparing the methylation states of the fetuses in fetu
to those of the other specimens, the following trend toward correlations of locus-specific
sites was observed: Stem cells (B) correlation > Host child (C) or Amnio case
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Figure 14: Heat maps for FIF
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Heat maps showing examples of methylation patterns for subsets of 30 loci (columns) for each of the
specimens (rows). Each square in the heat map shows the relative level of methylation for a specific
site evaluated (values range from 0 to 1, with bright green corresponding to sites that are
hypomethylated, while bright red corresponds to sites that are hypermethylated). Over the 485,764
sites interrogated, clusters of similar patterns were observed that were: (A) consistent for the FIF and
host child but not the other specimens (likely to be genotype driven); (B) limited to the FIF; (C)
common for the FIF and the stem cells but not the child/amnio (influenced by
environmental/developmental cues); (D) distinct for the stem cells; (E) distinct to peripheral blood
(shown) or amniocytes (not shown) or (F) similar across all specimens. The dendograms on the right
show the cluster analysis results for the specimens based on the entire data set [not the subset of
examples shown to illustrate the types of variation observed].
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Discussion

Here, we present the first case of fetus/fetuses in fetu for which a genome-wide
analysis of methylation patterns has been determined. The only other group to report
methylation patters in FIF is Miura et al. (2006), who analyzed methylation patterns between
the host/FIF duos for 2 kindreds using a targeted assessment of a single gene that is known to
be differentially methylated (imprinted). Based on their results, they concluded that the
embryonic timing of the implantation of the FIF could impact the methylation pattern of
genes in the FIF.

Epigenetic reprogramming is a critical process during the normal development of an
embryo. Upon fertilization, global demethylation takes place in whole genomic sequences
except for imprinted loci, which are maintained. This erasure is followed by a whole genome
de novo methylation. (Reik et al., 2001, Li, 2002, Owen and Segars, 2009) Since there is a
lack of studies investigating human embryos, most of the findings in embryogenesis come
from studies of mouse embryos. In mice, it has been shown that the paternal genome
undergoes demethylation rapidly and reaches the lowest levels of methylation before the twocell embryo stage (Haaf. T, 2006). However, the maternal genome imprints are maintained
up to the two-cell embryo stage, then the methylation marks start to gradually drop until after
the eight-cell embryo stage, when both paternal and maternal become equally demethylated
(Haaf. T, 2006 ). Genome-wide de novo methylation happens preferentially in the inner cell
mass o the blastocyst-stage embryos, thereby allowing for the establishment of the somatic
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methylation patterns in the embryo’s cells, which then differentiate to various embryonic
lineages (Haff , 2006, Mayer et al 2000a, Reik et al 2001, Dean et al. 2001, Li, 2002).

Given that FIF is thought to originate in the blastocyst-stage of embryogenesis as a result
of the unequal division of the inner cell mass, which is thought to be a stage that is important
for epigenetic reprogramming (Lord, 1956, Beaudoin et al 2004; Haaf, 2006), studies of
methylation patterns in FIF cases could provide insight regarding embryonic methylation and
development. In this study, we showed that the greatest level of variation in methylation
patterns between the FIFs and the host trio involved hypermethylation states. The three multipotent adipose-derived stromal cells showed the lowest density of methylation at
hypermethylated sites, followed by the two FIF, then the amniotic fluid cells and then the
genetically identical FIF host child.

A shortcoming of this study was our inability to study a similar tissue type (skin) from the
host child for comparison to the patterns seen in the fibroblasts from the FIF. However, the
methylation patterns observed suggest that the differences reflect changes beyond those
related to tissue-specific or genotype specific findings since the amniotic fluid cell patterns
were more closely related to the host child then the FIFs (similar phenotype [normal], but
different genotype and cell type). The observation of a higher density of hypermethylated sites
in the host child compared to the FIF is consistent with a lack of the FIF specimens to complete
the normal re-establishment of methylation patterns during embryogenesis. The data also
suggest that epigenetic changes acquired during development are more heavily influenced by
embryonic environmental cues than the developing embryo’s genotype since the genetically
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identical FIF and host child showed the greatest patterns of divergence. This is not surprising
since establishing epigenetic imprints in the fetus is very critical during the formation of the
blastocyst and it is known that the first trimester of pregnancy is very sensitive to
environmental influences. Nonetheless, there were subsets of genes that did appear to be
closely related to genotype, with other subsets being identified that had consistent methylation
patterns across all specimens.

The observation that the methylation patterns for the multi-potent adipose-derived stem
cells were more closely related to the FIF specimens than the other specimens is also
interesting. One could speculate that the FIF cells retain their multi-potent capacity due to a
failure to “silence” genes that would typically be methylated. The “cues” necessary for
initiating these methylation alterations may involve microenvironments from the surrounding
cells, rather than being strictly encoded through the organism’s genome. A full assessment of
the individual sites demonstrating differential methylation may provide clues as to genes/gene
networks that are most closely related to methylation status to allow for normal
embryogenesis to proceed.

In summary, further whole genome methylation studies of rare cases of fetus in fetu could
provide valuable insight about epigenetic patterns that are acquired during human
embryogenesis, as well as the influences those patterns play in directing tissue/morphological
development.
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